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resumo 
 
 
A fecundação é um processo complexo e faseado que culmina na fusão celular 
das membranas dos gametas, do citoplasma e do genoma. A CD81 é uma 
proteína tetraspanina que participa na interacção espermatozóide-oócito, 
estando presente na superfície do oócito. A CD81 também tem sido associada 
a outros processos biológicos, contudo a sua função específica e os seus 
mecanismos de acção não estão elucidados. A ligação entre a CD81 e as suas 
proteínas interactoras fundamenta o envolvimento da CD81 numa variedade de 
processos celulares e funções específicas. O desenvolvimento de um sistema 
de Dois Híbrido em Leveduras, anteriormente realizado no nosso laboratório, 
mostrou que a CD81 potencialmente interage com a Proteína Percursora de 
Amilóide (PPA). 
No presente trabalho, foi realizada a análise bioinformática das proteínas 
interactoras da CD81. A informação obtida permitiu a construção de uma rede 
de interações proteína-proteína, bem como a análise de enrequecimento de 
Ontologia de Genes. Adicionalmente, a expressão da CD81 foi avaliada nas 
linhas celulares CHO, GC-1 e SH-SY5Y e em espermatozóides humanos. A sua 
localização subcelular foi também analisada em espermatozóides humanos e 
na linha de neuroblastoma SH-SY5Y. Foram ainda realizados ensaios de co-
imunoprecipitacão nas linhas celulares CHO e SH-SY5Y, com a tentativa de 
provar a intercação física entre a CD81 e a PPA. A interação funcional entre 
estas duas proteínas foi estudada através da análise do efeito da 
sobreexpressão da CD81 nos níveis de PPA. Foram também realizados estudos 
de colocalização  entre a CD81 e algumas proteínas interactoras, nos 
espermatozóides humanos e na linha celular SH-SY5Y. Os interatores 
analisados, PPA, AKT1 e proteínas relacionadas com o citoesqueleto, foram 
obtidos da análise bioinformática previamente realizada. O efeito da CD81 na 
remodelação do citoesqueleto foi avaliado através da monitorização dos efeitos 
da sobre-expressão da CD81 nos níveis de actina e tubulina, bem como através 
da análise da colocalização entre a CD81 sobre-expressa e a F-actina. 
Os nossos resultados mostram que a CD81 está expressa em todas as linhas 
celulares testadas, providenciando a primeira evidência da presença da CD81 
em espermatozóides humanos. A marcação da CD81 foi predominantemente 
detectada na cabeça do espermatozóde e na peça intermédia, onde colocaliza 
com a PPA, bem como na região pós-acrossómica. Em adição, a CD81 
colocaliza com a PPA na membrana plasmática e nas projecções celulares das 
células SH-SY5Y, onde a sobre-expressão da CD81 influencia os níveis de PPA, 
efeito também observado nas células CHO. A análise de proteínas interactoras 
da CD81, como a AKT1 e proteínas relacionadas com o citoesqueleto, 
evidenciou que a CD81 está envolvida na remodelação do citoesqueleto, 
nomeadamente na motilidade dos espermatozóides, na migração celular e na 
neuritogénese. Estes resultados permitiram aprofundar o conhecimento das 
funções da CD81 e de alguns dos seus interactores, em espermatozóides e em 
células neuronais.   
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Fertilization is a multistep and complex process culminating in the merge of 
gamete membranes, cytoplasmic unity and fusion of genome. CD81 is a 
tetraspanin protein that participates in sperm-oocyte interaction, being present 
at the oocyte surface. CD81 has also been implicated in other biological 
processes, however its specific function and molecular mechanisms of action 
remain to be elucidated. The interaction between CD81 and its binding partner 
proteins may underlie the CD81 involvement in a variety of cellular processes 
and modulate CD81/interactors specific functions. Interestingly, in a Yeast two 
Hybrid system previously performed in our lab, CD81 has emerged as a putative 
interactor of the Amyloid Precursor Protein (APP).  
In the work here described, bioinformatics analyses of CD81 interacting proteins 
were performed and the retrieved information used to construct a protein-protein 
interaction network, as well as to perform Gene Ontology enrichment analyses. 
CD81 expression was further evaluated in CHO, GC-1 and SH-SY5Y cell lines, 
and in human sperm cells. Additionally, its subcellular localization was analyzed 
in sperm cells and in the neuronal-like SH-SY5Y cell line. Subsequently, co-
immunoprecipitation assays were performed in CHO and SH-SY5Y cells to 
attempt to prove the physical interaction between CD81 and APP. A functional 
interaction between these two proteins was accessed thought the analyses of 
the effects of CD81 overexpression on APP levels. A co-localization analysis of 
CD81 and some interactors proteins retrieved from the bioinformatics analyses, 
such as APP, AKT1 and cytoskeleton-related proteins, was also performed in 
sperm cells and in SH-SY5Y cells. The effects of CD81 in cytoskeleton 
remodeling was evaluated in SH-SY5Y cells through monitoring the effects of 
CD81 overexpression in actin and tubulin levels, and analyzing the co-
localization between overexpressed CD81 and F-actin. 
Our results showed that CD81 is expressed in all cell lines tested, and also 
provided the first evidence of the presence of CD81 in human sperm cells. CD81 
immunoreactivity was predominantly detected in the sperm head, including the 
acrosome membrane, and in the midpiece, where it co-localized with APP, as 
well as in the post-acrosomal region. Furthermore, CD81 co-localizes with APP 
in the plasma membrane and in cellular projections in SH-SY5Y cells, where 
CD81 overexpression has an influence on APP levels, also visible in CHO cells. 
The analysis of CD81 interacting proteins such as AKT1 and cytoskeleton-
related proteins showed that CD81 is involved in a variety of pathways that may 
underlie cytoskeleton remodeling events, related to processes such as sperm 
motility, cell migration and neuritogenesis. These results deepen our 
understanding on the functions of CD81 and some of its interactors in sperm and 
neuronal cells. 
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 Introduction  
1.1  Sperm cells and fertilization 
Fertilization is a multistep and complex process culminating in the merge of gamete 
membranes, cytoplasmic unity and fusion of genome, initiating the development of a new 
individual. This merge is achieved through gamete interactions, specifically cell adhesion and 
subsequent fusion of the gametes’ plasma membranes (PM). Although a key event in this process, 
there is still very little information about the mechanism or the molecules involved in membrane 
fusion1,2. Fertilization begins when free-swimming sperm approach oocyte within the oviduct. 
Mammalian sperm cannot fertilize the oocyte immediately when ejaculated and must first undergo 
a physiological change called capacitation (in the reproductive tract) and a subsequent 
morphological alteration known as the acrosome reaction when they contact with the zona 
pellucida (ZP) of the oocyte. After completion of the acrosome reaction, sperm penetrates the ZP, 
finally adhering and fusing with the plasma membrane of the oocyte. Gamete fusion results in egg 
activation, pronuclear formation and syngamy3,4 (Figure 1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Fertilization process: mechanism of sperm-oocyte interactions. PVS: Perivetelline space; ZP, Zona 
Pellucida Reproduced from24.  
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Sperm are remarkable and atypical cells with a peculiar functionality: they are produced in 
the testis of one organism, and upon release they invade the female tract and deliver their genetic 
material to an oocyte (fertilization). During spermatogenesis, spermatozoa became terminally 
differentiated. These highly specialized cells are composed of three main regions: the head, the 
midpiece, and the tail (Figure 2). The head comprises the condensed nucleus (in which DNA 
condensing histones are removed and replaced by protamines, resulting in a super condensed 
DNA), redundant nuclear envelope, and the acrosome vesicle. The acrosome is a large secretory 
vesicle holding hydrolytic enzymes that assist the sperm penetration though the ZP at fertilization. 
The sperm tail consists of a flagellum, a motile cilium that comprises an axoneme that consists of 
an array of microtubules in a typical 9+2 arrangement (two central microtubules surrounded by a 
ring of nine microtubules pairs). Other proteins structures are arranged around the axoneme, such 
as the outer dense fibres and fibrous sheath, adding strength and resistance to the tail. This fibrous 
sheath functions as a scaffold for proteins in signalling pathways that regulate sperm maturation, 
motility, capacitation and acrosome reaction. The sperm midpiece connects the head and the tail 
and is composed by a large number of mitochondria (where ATP production occurs through 
oxidative phosphorylation) that are spiral wrapped around the central flagellum5–11. During 
spermatogenesis most of the cytosol and redundant organelles such as the Golgi apparatus, 
endoplasmic reticulum (ER), lysosomes, peroxisomes and ribosomes are removed. The sperm cells 
are transcriptionally silent and it is generally accepted that they are translationally silent too. There 
are some findings indicating that mammalian spermatozoa contains nuclear-encoded mRNAs in 
addition to their ability to synthesize mitochondrial-encoded RNA and proteins. According to Gur 
et al. (2005)12, the ability of sperm cells to synthesize proteins is critical for the maturation step 
leading to successful fertilization. The sperm PM, tightly attached to the underlying cellular 
structures along the whole sperm body to provide rigidity, is highly polarized and dynamically 
reorganizes itself during capacitation and other fertilization processes, such as sperm-oocyte 
adhesion and fusion processes7,8,13 . 
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Figure 2. Sperm geometry: a mature sperm 
cell consists of head, midpiece and tail. The 
head is essentially divided into condensed 
DNA and acrosome. The miedpiece contains 
the mitochondrial sheath. The tail or 
flagellum is composed by microtubules that 
allow sperm motility. Reproduced from14.  
 
 
As soon as sperm cells are deposited in the female reproductive tract and pass the cervical 
mucus, they undergo many biochemical and physiological changes in a process called capacitation; 
this includes a change in the pattern of sperm motility known as hyperactivation, and the sperm 
becomes competent to fertilize an oocyte15,16.  The biochemical changes that occur in this process 
include an efflux of cholesterol from the PM leading to an increase in membrane fluidity and 
permeability to bicarbonate and calcium ions. This results in increased bicarbonate (HCO3-) 
concentration, intracellular pH, and increased Ca2+ and cyclic adenosine monophosphate (cAMP) 
levels4,17.  The process of capacitation can be divided into two signalling events: a) fast events such 
as the initiation of sperm motility, occurring as soon as the spermatozoa is released from the 
epididymis, and b) slow events such as changes in the motility pattern and the acquisition of the 
sperm capacity to undergo agonist-stimulated acrosome reaction (Figure 3)17,18.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Molecular basis of fast (a) and slow (b) events associated with sperm capacitation. Adapted from19.  
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Capacitation is regulated by two parallel pathways, one requiring activation of PKA and 
another involving activation of Ser/Thr protein phosphatases, such as PP2A. Taken together, sperm 
capacitation results in the induction of glycolysis in the sperm tail required for the hyperativated 
motility. In the sperm head it causes the redistribution of surface molecules, aggregation of lipid 
rafts and formation of a functional ZP binding protein complex20.  
Once capacitated, sperm cells demonstrate a vigorous swimming pattern considered to give 
sperm the strong thrusting power that allows them to penetrate the ZP4,21 . 
 
 
After capacitation sperm undergo a morphological change called acrosome reaction, 
initiating the process of fertilization. The sperm acrosome is a Golgi-derived organelle localized in 
the apical region of sperm head. The acrosome exocytosis is a multipoint membrane fusion event 
since the outer acrosome membrane and the PM fuse at multiples sites, and as a consequence, only 
the inner acrosome membrane becomes a new plasma membrane20,22. During the process of 
acrosome reaction this vesicle undergoes exocytosis and releases its contents including hydrolytic 
enzymes such as hyaluronidase (PH-20), which are required for the penetration of cumulus cell 
layers and the ZP for completing the sperm-oocyte fusion4,23. The sperm surface binds to at least 
three of the four human ZP proteins (ZP1, ZP3 and ZP4) by multiple proteins, most likely organized 
into ‘zona binding protein complexes’20,24.  Binding of a capacitated sperm to the zona matrix 
activates two prominent signalling pathways (Figure 4). One is the pertussis toxin-sensitive Gi 
protein-coupled receptor linked to PLCβ1. The other is a putative tyrosine kinase receptor coupled 
to PLCγ, which leads to activation of components involved in fusion of the outer acrosomal 
membrane with the sperm plasma membrane, resulting in the acrosome reaction23,24. 
The acrosome exocytosis enables the sperm to reach the perivitelline space and exposes 
the inner acrosomal membrane and the equatorial segment of the head, which is required for the 
sperm to fuse with the oocyte membrane20.  
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Although fascinating, the interaction between sperm and oocyte is yet poorly understood25. 
Currently, the term sperm-oocyte interaction includes two cellular events: sperm-oocyte adhesion 
and sperm-oocyte fusion (Figure 5). For cell-cell fusion, cell adhesion is a precursor step, mediated 
by adhesion molecules on the sperm and oocyte surfaces, which brings the membranes in close 
apposition. Ultimately, this membrane interaction leads to the actual fusion event, with mixing of 
the lipid bilayers, formation of the fusion pores, and establishment of cytoplasmic continuity 
between the two cells2.  
Figure 4. Schematic representation of various pathways involved in ZP-mediated acrosomal exocytosis; cAMP, 
cyclic adenosine monophosphate; DAG, 1,2-diacylglycerol; PKA, protein kinase A; IP3, 1,4,5-inositol triphosphate; 
PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; SOC, store-operated channel; VOCC, voltage-
operated calcium channel; ZP, zona pellucida. Adapted from23. 
Figure 5. Schematic diagram illustrating the distinct steps of sperm binding and fusion with the oocyte plasma 
membrane. Purple, equatorial segment; orange, inner acrosomal membrane. Reproduced from2. 
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During recent years, efforts have been made towards the identification of the molecular 
players in sperm-oocyte interactions and their function. Several molecules on the oocyte or the 
sperm side were classified essential, highly relevant, or associated with essential molecules. 
Although the concept of multiprotein complexes on both membranes has been accepted in recent 
years, the first known molecules directly implicated in mammalian fertilization have been only 
recently discovered1.  The proteins involved in sperm-oocyte interactions are summarized in Table 
1 (sperm proteins) and Table 2 (oocyte proteins).  
Table 1. Sperm proteins involved in sperm-oocyte interaction1,2,20,25–29. 
Protein Summary of Data 
Role in 
fertilization 
Binding partner 
Izumo 1 
Belongs to an immunoglobulin 
superfamily of type I membrane 
proteins; Izumo1 relocates during 
acrosome reaction from the 
anterior part of the sperm head 
to the sites where the fusion 
would take place. 
Izumo1-/- mice are 
completely 
infertile; essential 
for fertilization 
Juno 
ADAMs  
(A desintegrin and 
metalloprotease) 
Fertilin 
(ADAM 1 
and 
ADAM2) 
Fertilin is composed of two 
glycosylated transmembrane 
subunits (ADAM1B and ADAM2) 
that make a heterodimer. It is 
distributed on the plasma 
membrane over the entire sperm 
head. 
Adam-/-  knockout 
has serious defects 
in gamete 
membrane 
interaction 
ADAMs are binding 
partners for several 
members of integrin 
family expressed in 
oocyte (α9β1 integrin) 
ADAM3 
ADAM3 may have a role in 
regulating aspects of sperm 
function.  ADAM3 has been 
proposed to be a sperm protein 
that mediates sperm-ZP3 
interaction 
Adam3-null sperm 
bind poorly to the 
ZP. ADAM3 is not 
essential for fusion 
ADAM3 binds a ZP 
component(s) directly 
SPESP 1 (Sperm equatorial 
segment protein) 
Belong to the SPESP1 family. 
Localized in the equatorial region 
before acrosome reaction and a 
part of the SPESP1 fragment may 
remain in the equatorial segment 
after the acrosome reaction. 
Spesp1-/- males 
have sperm with 
reduced ability to 
undergo sperm-
oocyte fusion. 
Unknown 
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Protein Summary of Data 
Role in 
fertilization 
Binding partner 
SLLP1 ( Sperm Lyzozyme-Like 
Acrosomal Protein) 
Belong to the glycosyl hydrolase 
22 family; SLLP1 relocates into 
the equatorial segment after the 
acrosome reaction. 
Specific antibody 
against SLLP1 
blocked both 
fertilization and 
binding. 
SAS1B 
 
 
Table 2. Oocyte proteins involved in sperm-oocyte interaction1,2,20,25–28 . 
Protein Summary of data Role in fertilization Binding partner 
Juno (Folate receptor 
4) 
GPI-anchored extracellular 
protein on the oocyte surface. 
The exact molecule structure 
has not been fully examined. 
Juno-/- female mice are 
absolute infertile. 
IZUMO1 This 
interaction seems to 
represent a 
necessary and 
essential adhesion 
step rather that the 
exact fusogenic 
action. 
Tetraspanins 
CD9 
Members of the tetraspanin 
family. Through interactions 
with other proteins in cis, 
tetraspanins create 
tetraspanin-enriched 
microdomains, which are a 
distinct type of membrane 
microdomain. 
Cd9-/- oocytes failed to fuse 
with sperm. Recent 
observations suggest that the 
CD9 molecule is secreted 
from the oocytes in vesicle, 
translocating to the sperm 
surface and promoting in this 
way the fusion process. CD9 
is likely to function in 
conjunction with CD81. 
There is no evidence 
for an exact binding 
partner, as the 
interaction with 
IZUMO1, however 
tempting, has not 
been proved. 
CD81 
 
Cd81-/- mouse shows defects 
in female fertility and sperm-
egg interaction. Cd9-/-/ Cd81-
/- female mice are completely 
infertile 
CD9 
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Protein Summary of data Role in fertilization Binding partner 
Integrins 
Integrins are heterodimeric 
membrane proteins, made up 
of an α and a β subunit. 
Oocytes deficient in β1 
integrin show defects in 
sperm-oocyte binding and 
oocytes with reduced 
amounts of α9 support 
sperm binding and fusion less 
well than the control 
oocytes. 
α9β1 integrin 
interact with several 
ADAMs. 
GPI-anchored 
proteins 
GPI-anchored proteins 
possess a covalently linked 
glycosylated 
phosphatidylinositol moiety 
which serves to attach the 
protein portion of the 
molecule to the cell surface 
lipid bilayer. 
The absence of all the 
oocyte GPI-anchored 
proteins may alter the 
normal lipid domain 
composition and may 
change the repertoire of 
protein-protein interaction 
in lipid domains. 
Because tetraspanins 
localize in raft-like 
microdomains, it is 
possible that exists 
an association 
between these 
molecules. 
SAS1B (Sperm 
Acrosomal SLLP1 
Binding) 
SAS1B is an oolemal 
metalloprotease that is 
concentrated in a dome 
corresponding to the 
microvilli region and in the 
perivetelline space. 
Sas1b-/- mice showed a 
significantly lowered 
fertilization rate 
SLLP1 is believed to 
be one of the 
binding factors in the 
attachment-fusion 
machinery on the 
oocyte surface. 
 
 
Gamete’s proteins that participate in sperm-oocyte interactions not only may act as a 
binding partner for a molecule on the opposite gamete or as a fusogen, but they also may interact 
in cis with other membrane proteins and regulate those proteins function, organization or overall 
membrane order. Figure 6 shows a schematic diagram illustrating the molecules implicated in 
gamete membrane binding and fusion. 
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  Upon fusion, sperm activates the egg by inducing calcium oscillations and leading to the 
completion of the second meiotic cell division. This activation leads to exocytosis from peripherally 
located cortical granules, such as ovastacin-containing granules, which results in cleavage of ZP2 
and by its turn in a decrease of the affinity to sperm. This phenomenon is called the ‘zona reaction’ 
and prevents polyspermy4. 
  
Figure 6. Sperm and oocyte molecules implicated in gamete membrane interactions. Adapted from2 
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1.2 CD81: a member of the protein tetraspanin superfamily  
One of the oocyte proteins involved in sperm-oocyte interactions is CD81 (also known as a 
target of antiproliferative antibody 1, TAPA-1). CD81 is a 26 kDa integral membrane protein 
member of the tetraspanin family, an evolutionarily conserved family of membrane proteins, with 
at least 32 distinct family members in mammals30. Tetraspanins are defined by four transmembrane 
(TM) domains delimiting two extracytoplasmic regions of unequal size, a small extracellular loop 
(EC1) and a large extracellular loop (EC2), and by the presence of several conserved amino acids, 
including an absolutely conserved CCG motif and two other cysteine residues in the EC2 30. This 
family of proteins have been implicated in a multitude of biological processes, including fertilization 
of oocytes, susceptibility to infection, metastasis of cancer, and cell-cell interactions in the central 
nervous and immune systems. These activities are due to the association of different tetraspanins 
with each other and with other tissue type-specific proteins in the cell membrane. These 
associations take the form of tetraspanin-enriched microdomains (TEM) that form a dynamic 
membrane network known as the ‘tetraspanin web’31.  
CD81 was originally discovered in 1990 as a target of an antiproliferative antibody on 
human B cells, and subsequent studies have shown that it is involved in a surprising range of 
physiological responses32. This molecule is highly conserved in mammals and is expressed on most 
human tissues with notable exceptions of red blood cells and platelets33. CD81 is abundant on 
various types of endocytic membranes and has been widely used as an exosomal marker. The CD81 
gene has been mapped to chromosome 11p15.5 in human and in the syntenic region of 
chromosome 7 in mouse. Several other tetraspanin genes are located on chromosome 11 and 12 
and the genomic structure is shared by each of the tetraspanin genes, indicating that they derive 
from a common ancestral gene34.   
 
 
The molecular model of the complete CD81 structure was proposed in 2006 by 
Seigneuret35. These studies on the protein topology demonstrated that the two long hydrophilic 
domains of the molecule are extracellular (Figure 7). The EC1 domain, also referred to as the small 
cellular loop (SEL), is located between TM1 and TM2, and EC2 or LEL (large extracellular domain) is 
located between TM3 and TM4. The SEL is thought not to be involved in protein binding. The LEL 
domain is the most variable between the tetraspanin family members. The sequence variability 
within LEL is clustered in one hypervariable region that is coded by exon 6. This exon also codes for 
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the short CCG motif, conserved in all tetraspanins. The LEL region is folded into a mushroom-like 
structure as a result of two disulphide bridges. The crystal CD81 structure shows helical regions (a, 
b and e) that are conserved among the tetraspanins and form a tetraspanin-homodimerization 
interface. The mushroom-like patch is formed by helices c and d, and mediates specific lateral 
protein-protein interactions and ligand binding32,33,36.  
 
 
 
 
 
 
 
 
Figure 7. Structural features of tetraspanins. Reproduced from37 .  
 
CD81 consists of four TM domains: TM1 and TM2 flank the SEL, whereas TM3 and TM4 
flank the LEL. Each TM domain contains conserved polar and non-polar aminoacid residues. These 
conserved residues in TM 1, 3 and 4 are responsible for a proper tetraspanin biosynthesis and 
maturation via intramolecular interactions, and contribute to the formation of the tetraspanin web 
through hydrophobic interactions between tetraspanins. Despite their short length, the 
cytoplasmic regions of tetraspanins (the cytoplasmic tails and short inner loop), can participate in 
various functions. These domains contain highly conserved cysteine residues that provide sites for 
palmitoylation, which contributes to the clustering of tetraspanin microdomains. The N-terminal 
intracellular CD81 contains two palmitoylatable cysteines, and the cytoplasmic C-terminal domain 
is involved in the sorting and targeting of CD81 to a determined intracellular region, and can 
mediate interactions with cytoskeletal or signalling proteins33,36,38.  
CD81 is a nonglycosylated protein, differing from other tetraspanin proteins that are 
glycosylated in either one of two extracellular domains. The CD81 protein undergoes 
posttranslational modifications by acylation with a fatty acid, not necessarily myristic acid33. 
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As mentioned above, one of the most striking features of tetraspanins is their ability to form 
lateral associations with multiple partner proteins, including each other, in a dynamic assembly 
described as the ‘tetraspanin web’. The composition of the web is cell type-specific, where 
partnerships are formed with cell surface receptors, adhesion molecules, and transmembrane 
signalling proteins (Figure 8). The tetraspanin web mediates the cross talk between cell surface 
stimuli and intracellular signaling pathways, allowing cells to respond to a constantly changing 
environment in a specific and highly regulated manner31.  
 
 
 
 
 
 
 
 
 
 
 
 
Through the use of different detergents in tetraspanin co-immunoprecipitations, three 
levels of interactions in the tetraspanin web have been proposed: primary, secondary and tertiary. 
Primary interactions have been referred to direct associations within the tetraspanin web with their 
non-tetraspanin partner molecules. Some associations with partners are highly stoichiometric, are 
highly avid and retained after lysis in harsh detergents such as 1% NP-40 or 1% Triton X-100. The 
most common primary partners of tetraspanins are specific members of the integrin and of the 
immunoglobulin superfamilies and these partnership can be formed with the extracellular domains 
of the interacting molecules. The secondary interactions have been referred to the ‘tetraspanin-
tetraspanin associations’ and are the weaker interactions between direct complexes. These 
interactions are not disrupted by mild detergents (as 1% Brij 96 or 1% Brij 97), and are not 
Figure 8. Membrane clustering of tetraspanin-enriched microdomains. A. Aerial view of tetraspanin-partner 
and tetraspanin-tetraspanin interactions. B. Side view of lateral associations of tetraspanin with partner 
molecules. Clustering is facilitated by palmitoylation. Tetraspanins are shown in shades of green; partners of 
the immunoglobulin superfamily are shown in red and brown; and partners of the integrin are in blue. 
Reproduced from39.  
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stoichiometric. Recent studies have demonstrated that palmitoylation is necessary for the 
maintenance of these secondary tetraspanin-tetraspanin interactions. The tertiary interactions 
refer to the indirect associations of tetraspanins with additional proteins. These interactions are 
not disrupted in mild detergents, such as 1% CHAPS or 1% Brij 98. Functionally, these interactions 
cluster with cholesterol in tetraspanin-enriched microdomains, enabling lateral dynamic 
organization in the membrane and cross-talk with intracellular signalling and cytoskeletal 
structures39,40.  
The tetraspanin-partner associations occur during the biosynthesis of tetraspanins. The 
web assembly may occur in multiple steps in conjunction with trafficking within the different 
cellular compartments in which web subunits are formed. Early in biosynthesis, tetraspanins can 
form specific interactions with their associated partner proteins in the ER, serving as building blocks 
for the assembly of the tetraspanin web. Tetraspanin-tetraspanin interactions are likely to form in 
the Golgi upon palmitoylation, serving as building blocks for the assembly of large multicomponent 
cell-surface complexes39.  
 
 
A major difficulty in the study of tetraspanins is to identify functions that are specific for a 
given tetraspanin, and to determine how this function relates to specific tetraspanin-associated 
proteins. CD81 has been implicated in immune cell functions and can directly associate with EWI-2 
and EWI-F, a pair of cell surface proteins of the immunoglobulin superfamily. CD81 supports 
maturation and surface expression of EWI-2, which modulates integrin-dependent cell motility and 
spreading. Antibody crosslinking of CD81 can co-stimulate T cells, suggesting positive effector roles. 
On B cells CD81 is required for molecular organization and efficient collaborations between the B 
cell receptors and its partners (CD21, CD19 and various signalling enzymes). Also, CD81 associates 
with and facilitates the biosynthesis of CD19, a molecule that plays a role in the B-cell receptor 
signalling. CD81 also closely associates with the α4β1 integrin, regulating α4β1 adhesion under 
shear flow conditions. CD81 plays a specific role in various human infection diseases: it is essential 
for the entry of malaria parasite into hepatocytes; its expression in immune cells is associated with 
HCV-induced pathogenesis; CD81 has been identified as a cell-surface receptor for hepatitis C virus 
(HCV)30,40.  
CD81 modulates cell signalling events, affecting processes such as cell proliferation, 
apoptosis and tumour metastasis. CD81 interacts with different cytoplasmic molecules, facilitating 
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the activation of signalling cascades. The association of CD81 with type II phosphatylinositol 4-
kinase (PI4K) may play a role in cell migration, bacterial infection and tumour cell proliferation. 
Recent studies strongly suggest that CD81 control cell migration due to its interaction with the small 
GTPase Rac. Further CD81 and CD9 positively modulate the activation of the extracellular signal-
regulated kinase 1/2 (ERK1/2)/MAPK pathway to induce proliferation. CD81 and CD9 are closely 
related tetraspanins that have been linked to several processes, including apoptosis, and cell-cell 
fusion processes, such as like sperm-oocyte fusion. Few recent studies have started to implicate 
CD81 in nervous system physiology30,40.  
 
1.2.3.1     CD81 in fertility  
From the membrane molecular players involved in mouse fertilization, only three so far 
have been shown to be essential: Izumo1 on the sperm surface, its oocyte-based receptor Juno, 
and the tetraspanin CD9 on the oocyte surface. These molecules are also present on human oocyte 
and sperm cells. CD9 is not the only tetraspanin expressed by human and mouse oocytes, which 
also express CD81, shown to associate with tetraspanin-enriched membrane structures on the 
surface of oocytes27,41. 
The lack of CD81 in the mouse female induces fertility defects, and the use of an anti-CD81 
mAb partially inhibited sperm-oocyte binding and fusion42. The role of CD81 in sperm-oocyte fusion 
was demonstrated by in vitro insemination using Cd81 -/- knockout mice. Deletion of the Cd81 gene 
in mice results in a 40% reduction of female fertility. Cd9-/- Cd81-/- double knockout mice were 
completely infertile41.   
Tanigawa et al. (2008) demonstrated that CD81 is continuously expressed in the oocyte and 
in cumulus cells surrounding ovulated oocytes. These results indicate that the sperm may 
encounter CD81 on the somatic cells surrounding oocytes before sperm and oocyte directly 
interact. When Cd81-/- oocytes are incubated with sperm, some of the sperm that penetrated into 
the Cd81-/- oocytes perivitelline space fail to undergo the acrosome reaction. The impaired fusibility 
of CD81-/- oocytes may thus be partially caused by failure of the acrosome reaction43. A recent study 
performed by Ohnami et al. (2012) shows that oocyte CD81 was mainly localized at the inner 
portion of ZP, and may be involved in any step of fusion-related events prior to membrane fusion 
(Figure 9). Before the sperm-oocyte fusion, CD9 inside the PVS is transferred to the sperm 
membrane44. The CD9-containing membrane fragments are transferred from the oocyte to sperm 
via “exosome-like” vesicles. This interaction between membranes could be involved in the 
activation of sperm molecular complexes involved in binding and/or fusion with the oocyte 
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membrane45. Ohnami et al. (2012) suggest that CD81 may help to transfer CD9 of the oocyte into 
the sperm membrane through the formation of a complex between them44.  
 
 
 
 
 
 
 
 
 
 
 
 
Figura 9. Schematic representation of the distribution of the CD81 tetraspanin in oocytes and sperm upon 
fertilization. Before fertilization, CD81 localizes in the inner region of the ZP. When the sperm penetrates the 
PVS, CD81 and CD9 appears to adhere to the sperm surface via exosomes. Orange area, CD81-localized area; 
light blue area, CD9-localized area; ZP, zona pellucida; PVS, perivitelline space. Reproduced from44. 
 
 Interestingly, CD81 was one of the most abundant interactors that appeared in a Yeast Two-
Hybrid screen of human testis cDNA library previously performed46. The protein used as bait, and 
whose interactors we were studying, was the Amyloid Precursor Protein, APP. 
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1.3 Amyloid Precursor Protein (APP) 
Since the molecular cloning of the APP gene in 1987, the functions of APP and its cleavage 
products have been subject of intense investigation. APP,  located in chromosome 21, is the most 
well studied member of APP family due its role in Alzheimer´s disease(AD)47–50. AD is the most 
prevalent neurodegenerative disorder and it is characterized by the presence of neurofibrillary 
tangles and amyloid plaques in the brain. Neurofibrillary tangles consist largely of 
hyperphosphorylated twisted filaments of the microtubule-associated protein tau. Extracellular 
amyloid plaques are deposits of differently sized small peptides, ranging in size from 38 to 44 
aminoacids and called β-amyloid (Aβ), derived from sequential proteolytic cleavages of its APP 
precursor51.  
 
APP is a member of an evolutionary conserved gene family that also includes the 
mammalian APP-like protein-1 and -2 (APLP1 and APLP2). These proteins are highly homologous, 
sharing ~38-51% amino acid sequence identity52,53. The nearest APP-relative is APLP2 in which a 
segment of the deduced polypeptide (position 694-763) has 70.6% homology with the 
transmembrane cytoplasmic domain of the APP54,55.  This family is conserved across a variety of 
species, and members can be found in invertebrates, including C. elegans (APP-like, APL-1) and D. 
melanogaster (APP-like, APPL)56,57. 
 All APP family members are type 1 integral membrane proteins with a single membrane-
spanning domain, a large ectoplasmic N-terminal regions and a shorter cytoplasmic C-terminal 
region. The APP sequence can be divided into multiple distinct domains, as demonstrated in Figure 
10. The ectoplasmatic region of APP, which constitutes the major part of the protein, can be divided 
into E1 and E2 domains. The E1 domain can be further subdivided into a heparin-binding/growth 
factor-like domain (HFBD/GFLD) and a metal binding domain (cooper-binding domain and zinc-
binding domain). The E1 domain is followed by an acidic region (Ac) and a Kunitz-type protease 
inhibitor (KPI) domain (that is subject to alternative splicing in both APP and APLP2). The E2 region 
consists of another HFBD/GFLD and a RERMS motif. The cytoplasmic region of APP contains a 
protein interaction motif, namely the YENPTY sequence, which is conserved in all APP homologues 
and participated in APP/APLPs endocytosis. The Aβ domain derived from the region of the protein 
encoded by parts of exons 16 and 17 is unique to the APP protein (Figure 10)58,59. 
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The mammalian APP gene contains 18 exons (exons 1-13, 13a, and 14-18), of which exons 
7, 8 and 15 can be alternatively spliced and generate multiple isoforms that are named according 
to their length in amino acids: L-APP 677, APP695, L-APP696, APP714, L-APP733, APP751, L-APP752, 
APP77060–62 (Figure 11). APP is ubiquitously expressed, but the relative abundance of each isoform 
varies according to the cell type. The predominant transcripts are APP695, APP751 and APP770, in 
which APP695 isoform is mainly found in neuronal tissue, whereas APP751 is the predominant 
variant elsewhere62.  The APP transcripts excluding exon 15 were first discovered in peripheral 
leukocytes and immunocompetent cells of the brain and where named leukocyte-derived APP (L-
APP); these are ubiquitously expressed with the exception of neurons63.  
 
 
 
 
 
 
 
 
 
Figure 10. Schematic illustration of the domain organization of the members of APP protein family. All 
members share conserved E1 and E2 extracellular domains, an acid domain (Ac) and the internalization 
YENPTY motif in the carboxyl terminus. Note that Aβ is unique for APP. HFBD/GFLD, Heparin-binding/growth 
factor-like domain; CuBD, Copper binding domain; ZnBD, Zinc binding domain; KPI, Kunitz-type protease 
inhibitor domain. Adapted from58,59. 
Figure 11. Exon structure of APP isoforms. The alternatively spliced exons are indicated in colours (E7, E8 and 
E15).  E7, exon 7 ( KPI domains); E8, exon 8; E15, exon 15; Aβ, beta-amyloid. 
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Like APP, APLP2 contains three exons that can be alternatively spliced. Four APLP2 isoforms 
are denoted as L-APLP2 isoforms in analogy to alternative splicing of APP exon 15. APLP1 gene does 
not give rise to alternatively spliced exons, producing a single transcript60. APLP2, similarly to APP, 
is ubiquitous, whereas APLP1 is found primarily in cells of the nervous system64.  
 
 
APP is produced in large quantities in neurons and is very rapidly metabolized. Initially 
targeted to the secretory pathway, it is proteolytic processed into various fragments during its 
intracellular trafficking65 (Figure 12). 
 
 
 
 
 
 
 
 
 
APP is synthetized in the endoplasmic reticulum (ER) and then transported though the Golgi 
apparatus to the trans-Golgi-network (TGN). From the TGN, APP can be transported in TGN-derived 
secretory vesicles to the PM (Figure 12, step 1). During the transport from the ER to the PM, APP 
can undergo post-translational modifications by N- and O-linked glycosylation, ectodomain and 
cytoplasmic phosphorylation, and tyrosine sulphation. Only a small fraction of APP remains in the 
plasma membrane, whereas the majority of APP localizes in the TGN. On PM, APP undergoes 
proteolytic processing or is internalized due to the presence of its YENPTY internalization motif 
(Figure 12, step 2). Following endocytosis, APP is delivered to endosomes, and a fraction of the 
endocytosed molecules is recycled to the cell surface. Significant amounts of internalized APP also 
undergo degradation in lysosomes (Figure 12, step 3)66–68. 
The proteolytic processing of APP can be divided into two different pathways: the 
amyloidogenic pathway, which leads to generation of Aβ, and the nonamyloidogenic pathway 
(Figure 13). Both pathways are mediated by at least three cleavage events. In the non-
Figure 12. Intracellular trafficking of APP. 
Reproduced from66. 
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amyloidogenic pathway APP is cleaved approximately in the middle of the Aβ region by α-secretase, 
which generates a soluble N-terminal ectodomain termed sAPPα, that is release from the cell 
surface, and a truncated APP C-terminal fragment (CTF) (αCTF or C83). This fragment is 
subsequently cleaved by γ-secretase, leading to the secretion of a small non-pathogenic peptide p3 
and a free APP intracellular domain (AICD) which is released into the cytosol. In the amyloidogenic 
pathway, the β-secretase activity initiates Aβ generation by shedding a large part of the ectodomain 
of APP (sAPPβ) and generating an APP CTF (βCTF or C99). This fragment is then cleaved by γ-
secretase, generating Aβ and AICD. This final cleavage is not precise and under physiological 
conditions can occur at least between aminoacids 37 and 43 of the Aβ domain, generating Aβ1-40, 
Aβ1-42, carboxyl-terminal-truncated and amino-terminal-truncated Aβ peptides59,65,66,69,70.  
 
 
 
Although APP processing has been widely studied, the location of the secretase activities 
within the cell, and the identification of the enzymes involved have not yet been fully elucidated. 
α-secretase is a zinc metalloproteinase and is a member of the ADAM (A Desintegrin and 
Metalloprotease) family. Three of this family members have been suggested to be α-secretase: 
Figure 13. APP processing involves proteolytic cleavage by several secretases. The amyloidogenic pathway 
releases Aβ peptides through cleavage by β- and γ-secretases. The non-amyloidogenic pathway is initiated 
by α-secretase cleavage, which occurs in the middle of the Aβ domain, and results in the release of several 
soluble APP fragments. Aβ, β-amyloid; APP-CTF, APP C-terminal fragment; AICD, APP intracellular domain. 
Adapted from70.  
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ADAM9, ADAM10, and ADAM17. α-cleavage occurs at the PM and in intracellular post-Golgi 
compartments. Beta-site amyloid precursor protein cleaving enzymes 1 and 2 (BACE1 and BACE2) 
were identified as the major β-secretases. BACE is a membrane-bound aspartyl proteases with a 
characteristic type I transmembrane domain. The optimal pH of BACE activity agrees with the β-site 
cleavage of APP taking place in more acidic cellular compartments, such as the endosomes. BACE 
cleavage has also been suggested to occur in the PM lipid rafts. γ-secretase is an aspartyl protease 
with low sequence specificity that cleaves the substrate within its transmembrane domain. This 
enzyme is a protein complex that consists of anterior pharynx defective 1 (APH-1), nicastrin, 
presenilin 1 or 2 (PS1 or PS2), and presenilin enhancer-2 (PEN-2). The existing in vivo and in vitro 
data on presenilin point it as the responsible for the aspartyl γ-secretase activity. Noteworthy, there 
is some evidence that Aβ1-40 and Aβ1-42 are generated in different cellular compartments59,65,66,69. 
Of note, although the sequences where the various secretases cleave are very different in the two 
mammalian homologous, both APLP1 And APLP2 are believed to be proteolytically processed in a 
similar way as APP59.  
 
 
Although APP and its homologues have been the subject of several studies, the 
physiological functions remains largely unknown. Several in vitro and in vivo studies have yielded 
strong evidence for the roles of APP, APLP1 and APLP2 in the developing and adult nervous system, 
in cell adhesion, neuronal survival, neurite outgrowth, synaptogenesis, vesicular transport, 
neuronal migration, modulation of synaptic plasticity, calcium metabolism, and insulin and glucose 
homeostasis. APP-derived proteolytic fragments mediate various and sometimes antagonist 
functions. Therefore, the net effect of full-length APP in cellular activity may be a combination of 
its metabolites´ functions. The N-terminal fragment, sAPPα, is neuroprotective, promotes neurite 
outgrowth and synaptogenesis, acts as a growth factor, and regulates cell adhesion. On the other 
hand, sAPPβ fragment can stimulate axonal pruning and neuronal cell death. The Aβ peptide has 
neurotoxic effects resulting in a neurodegenerative cascade leading to synaptic dysfunction and 
formation of intraneuronal fibrillary tangles. Although excessive Aβ causes neurotoxicity, low levels 
can positively modulate synaptic plasticity, revealing a novel physiological function for Aβ. The AICD 
fragment has been shown to possess transactivation activity and can regulate transcription of 
multiple genes, induce apoptosis, and may play a role in sensitizing neurons to toxic stimuli. Full 
length APP has been suggested to function as a cell surface receptor contributing to cell adhesion 
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and cell-cell interactions via its extracellular domain and possibly though trans-dimerization 
(reviewed in59,65,71).  
 
1.3.3.1  APP and fertility 
Although APP has been extensively investigated in association with AD pathology of the 
brain, APP biological functions are not restricted to the nervous system. Based on findings using the 
double App and Aplp2 knockout mice, APP and APLP2 have been implicated in fertilization and may 
play a role in mammalian fertility. Knockout (KO) mice, homozygotes to either App (-/-) or Aplp2 (-
/-) were healthy and fertile. Contrary to this data, 80% double KO mice to App (-/-) and Aplp2 (-/-) 
die within the first week and the surviving mice are infertile (9 of 10 females and all males). This 
findings suggests that APP and APLP2 can substitute each other functionally and are required for 
early postnatal development, normal growth, strength/balance, and fertility72.  
In 1990, Shoji and Kawarabayashi73 demonstrated that native APP is present in acrosomes 
and in growing flagella, suggesting that APP appears in particular phases of spermatogenesis, 
especially the head and tail formation phase in spermatids.  
A human sperm membrane protein termed YWK-II (latter shown to be homologous with 
APLP2) was immunolocated in male and female gametes. YWK-II/APLP2 is expressed in the mouse 
PM that envelops the acrosome, suggesting its participation in sperm-egg interactions. YWK-
II/APLP2 may be a Gαo-coupled receptor and was shown to interact with Müllerian-inhibiting 
substance (MIS), which is well known to be required for sex determination. These interactions 
suggest that YWK-II/APLP2 may participate on germ cell differentiation and sperm metabolism74–76. 
Given the high degree of homology between APP and APLP2, and taking into account the Shoji and 
Kawarabayashi (1990) findings, da Cruz e Silva group performed a study in order to characterize the 
subcellular distribution of the APP superfamily members in human sperm. This study was carry out  
using a battery of antibodies that either recognize APP-specific epitopes or epitopes shared with 
other APP family members77. The results of this study show that in human sperm, the tail mainly 
expresses full-length KPI-positive APP, the mid-piece mainly expresses KPI-positive APLP2 variants, 
the equatorial region mainly contain KPI-containing ALPL2 variants, and the surface of the entire 
spermatozoa contains APP and/or APLPs, with particular abundance on the head (Figure 14). These 
results prove the presence of APP itself in human sperm. According to the authors the presence of 
APP family members along the entire length of the tail may be related to signalling events involved 
in sperm motility, whereas their presence on the surface, especially in the equatorial region, 
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suggests their involvement in sperm-oocyte interactions77. However, no binding partner has been 
described for APP in sperm-oocyte interactors or many other sperm functions. 
 
 
 
 
  The identification of the protein networks interacting with APP can be very useful to 
approach APP functions. To date, most proteins interacting with APP have been identified in the 
brain, but less is known about the pathways involved in testis and sperm functions. 
  In order to identify tissue-specific interacting proteins to approach APP functions in sperm 
and testis, our lab performed a Yeast Two-Hybrid (YTH) screen of a human testis cDNA library, using 
full-length human APP as bait, followed by a comprehensive bioinformatics analysis. From the total 
of the clones screened, 147 were positive and encoded 37 known proteins. Only one protein had 
previously been identified as an APP interacting protein (RANBP9)46.  The analysis of the YTH screen 
revealed that one of the most abundant interactions was with CD81 (5 out of the 147 positive 
clones). The study included a network structure and bioinformatics analyses to determine the 
biologically relevant APP protein-protein interactions and revealed prominent topological 
properties for CD8146.  
  
Figure 14. Schematic representation of the APP superfamily distribution in human sperm. Taken from77. 
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 Aims of the Thesis 
 
 CD81 is involved in reproduction, namely in sperm-oocyte interaction, but few is known 
about the molecular mechanisms involved in this CD81 function. APP and APLPs are expressed in 
the plasma membrane of the sperm head, a region involved in sperm-oocyte interaction, and APP 
has revealed to be a putative CD81 interacting protein. Taking these data into account, and the 
facts that APP is a very important protein of the nervous system and the CD81 biological functions 
in neuronal cells are also still far from clear, CD81 has emerged as a very interesting target of study 
for us. 
 The main general aim of this thesis was to expand the knowledge of CD81 in sperm cells 
and in a neuronal cell line, though the study of some of its interactions with proteins such as APP. 
The specific objectives set to attain this goal were to: 
- Perform a bioinformatics analysis of CD81 interacting proteins; 
- Characterize the expression of CD81 in sperm cells and in different cell lines, including 
a neuronal-like cell line; 
- Determine and characterize the CD81-APP physical and functional interaction; 
- Evaluate the co-localization of CD81 with some of its interacting proteins, in sperm-cells 
and in a neuronal cell line. 
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 Materials and Methods 
3.1 Bioinformatics analyses  
 
The identification of proteins that interact with human CD81 was carried out using the 
public database ‘Biological General Repository for Interaction Dataset’ (BioGrid)78. Only the 
interactions that were curated in Homo sapiens have been included.  In addition, a literature survey 
was conducted to complement data on other interactions of CD81 absent from BioGrid by searching 
these in PubMed. The proteins involved in this study were collected with their own ID: gene symbol 
(www.genecards.org/) and UniProtKB (www.uniprot.org/uniprot/?query=&sort=score).The gene 
symbol of all collected proteins were loaded into the GeneMANIA79 tool to generate a protein-
protein interaction network. The network was generated using only data on physical interactions 
and using the “Biological process based” as the network weighting method.   
 
 
The Gene Ontology (GO)-term enrichment analysis was carried out using PANTHER - Protein 
Analysis Through Evolutionary Relationships80 according to GO annotation (‘biological processes’, 
‘molecular functions’ and ‘cellular component’). The gene symbol of all collected proteins were 
loaded into PANTHER and the enrichment of specific GO-terms was tested using the “statistical 
overrepresentation test”, followed by the Bonferroni multiple testing correction to control for the 
false discovery rate.  
Similar to the GO-term enrichment analysis, cell-signalling pathways were also analysed 
using the “statistical overrepresentation test” implemented in PANTHER.  
 
3.2 Preparation of CD81 cDNAs  
The mApple-CD81 (Plasmid #54875) and pCDM8 hCD81 (Plasmid #11588) plasmids were 
purchased from Addgene (Cambridge, UK). Both plasmids encoded CD81, but mApple-CD81 has an 
orange-fluorescing tag (mApple) on N-terminal. The mApple-CD81 plasmid has bacterial resistance 
to kanamycin and pCDM8 hCD81 to ampicillin.  
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The plasmids were acquired as transformed bacteria in stab culture format. After being 
received, the bacteria were streaked from the stab onto a Luria Broth (LB) agar plate to isolate 
single colonies, further used to amplify and purified the plasmidic DNA by “Midiprep” using 
NucleoBond® Xtra Midi (Macherey-Nagel, Germany). One isolated colony of streaked LB agar plate 
was used to inoclute 3 ml of LB medium containing the appropriate antibiotic, and incubated for 
16-18 h at 37oC with shaking (200 rpm). An aliquot of 150 µl was used to inoculate 150 ml of LB 
medium, also with the appropriate antibiotic, and the culture incubated overnight (ON) at 37oC with 
shaking (200 rpm). Cells were centrifuged at 6000 g, for 10 min at 4oC, the supernatant discarded, 
and 8 ml of resuspension Buffer RES added. After resuspension, 8 ml of lysis Buffer LYS was added, 
gently mixed by inverted the tube 5 times and incubated at RT for 5 min. Once the solution became 
clear and viscous, 8 ml of neutralization Buffer NEU was added to the lysate cells and then 
centrifuged at 12000 g for 10 min. Following, a NucleoBond® Xtra column filter was equilibrated 
with 12 ml of equilibration buffer EQU, placed into a 50 ml disposable plastic tube and the 
supernatant was poured into the column. The column filter was washed with 5 ml of equilibration 
buffer EQU and then discarded. The column was then washed with 8 ml of washing buffer WASH. 
To elute the DNA, the column was transferred to a new 15 ml plastic tube and 5 ml of elution buffer 
EDU was added. The precipitation of eluted DNA was carried out by adding 3.5 ml RT isopropanol 
and the DNA recovered by centrifugation (15000 g, 30 min at 4oC). The supernatant was discarded, 
and the pellets rinsed with 2 ml of 70% ethanol RT. The solutions were centrifuged at (15000 g, 5 
min) the supernatant again removed, and the pellet allowed to dry. After all traces of ethanol have 
disappeared, the DNA was resuspended in Milli Q water and stored at -20oC. DNA concentration 
and its 260/280 nm purity ratio were calculated upon spectrophotometer measurement.  
 
3.3 Mammalian cell assays 
In the impossibility of performing sperm-oocyte interaction assays in our lab, immortalized 
cell lines were used to study the putative CD81 and APP interaction. The Chinese hamster ovary 
(CHO) cell line, of ovary nature, and the CG-1 spg cell line, derived from postnatal day 10 mouse 
testis and described as an intermediate spermatogenic cell type between type B spermatogonia 
and primary spermatocytes, were used. SH-SY5Y cell line was also used, due to its neuronal nature 
and its good expression of endogenous APP. The SH-SY5Y human neuroblastoma cells are originally 
derived from the cell line SK-N-SH, established from a bone marrow biopsy of a neuroblastoma 
patient.  
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CHO cells were maintained in Ham’s F-12 nutrient mixture (F-12; Sigma-Aldrich) containing 
2 mM L-glutamine, 10% heat inactivated Foetal Bovine Serum (FBS; Gibco) and 1% 
antibiotic/antimycotic (AA) mix (Gibco). GC-1 cells were maintained in Dulbeco’s Minimum 
Essential Media (DMEM; Gibco) supplemented with 10% FBS (Gibco) and 1% AAs mix (Gibco). SH-
SY5Y were maintained in 10%FBS/1% AA mix-supplemented Minimum Essential Media (MEM):F12 
(1:1). All cell lines were maintained in a 5% CO2 humidified incubator at 37oC, and subcultured when 
a 70-80% confluence was reached. 
 
Fresh sperm samples were obtained from patients undergoing routine semen analysis or 
fertility treatments in the Human Reproduction Service at University Hospitals of Coimbra. Patients 
signed informed consent forms and the samples were used in accordance with the appropriate 
Ethical and Internal Review Board of the participating institution. Sperm samples were obtained by 
masturbation after 3-5 days of sexual abstinence and routine seminal samples analysis was 
performed according to the World Health Organization (WHO) guidelines81. All the samples used in 
this study had no detectable leukocytes (or any other round cells). After liquefaction, sperm cells 
were prepared by direct swim-up and allowed to capacitate in a supplemented Earl’s balance salt 
solution (sEBSS) for at least 3 h at 37oC under 5% CO2/95% air before starting the experiments.  
 
Since the CHO line was a recent cell line used in our laboratory, we first characterize its 
growth. A CHO cells growth curve was determined by using two different methods of cell viability 
analysis, the Trypan blue (TB) exclusion dye method and the Resazurin metabolic colorimetric assay. 
CHO cells suspended in growth medium were seeded (1x104 cells/well) of 6-well plate 
(Corning) and incubated at 37oC in a humidified 5% CO2. At a daily basis, media was substituted 
with fresh medium supplemented 10% of a resazurin solution [0.1 mg/ml resazurin salt solution 
(Sigma- Aldrich) in phosphate buffer solution (PBS; Pierce, Thermo Scientific)] with an end-volume 
of 1 ml per well. The cultures were incubated for 4h at 37oC in 5% CO2. Following this incubation 
period, the resazurin-containing growth medium was collected, the cells washed with PBS, 
suspended in PBS (volume depending on the average cell number), an aliquot mixed 9:1 with Trypan 
Blue solution (Sigma-Aldrich) was loaded in a hemocytometer, and cells were scored. In parallel, 
the rate of resazurin conversion to resofurin by metabolically active cells was evaluated via 
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spectrophotometric analysis at 570 and 600 nm (Infinite M200 microplate reader; Tecan 
Männedorf, Switzerland) of the resazurin-containing medium. A final optical density (O.D.f) was 
determined for each sample, as follows: (O.D. 570/O.D.600)-(O.D.570c/O.D. c 600), where ‘OD.c’ 
are the O.D.s of control samples (fresh medium supplemented with resazurin, never in contact with 
cells).  This procedure was carried out during 10 days, at the same hour, in triplicate.  
 
 
 
In order to study the physical and functional interactions between APP and CD81, transient 
transfections of their cDNAs were performed in CHO and SH-SY5Y cells. Cells were plated and 
growth on plastic culture dishes (6-well or 100 mm) (Corning), 24 h before transfection, to be at 
~70-80% confluence at the time of transfection. The growth medium was changed immediately 
prior to the transfection procedure. Cells were transient transfected with CD81 cDNAs (mApple-
CD81 and untagged pCDM8 hCD81), alone or together with APP cDNAs (Wt APP-GFP and untagged 
pRC/CMV APP).The empty vectors (mApple, pCDM8, pEGFP-N1 and pRC/CMV) were single- or co-
transfected as experimental controls.  
All the transfection procedures were performed using the TurboFect™ reagent (Fermentas 
Life Science), a cationic polymer that forms a positively charged complex with DNA that is easily 
endocytosed by eukaryotic cells. For each well of 6-well plate, a certain amount of different cDNA 
was diluted in 100 µl of serum-free growth medium. After gently vortexing, a ratio of 1:2 µl 
TurboFect™ reagent was added to the DNA, mixed and incubated during 20 min at RT. This solution 
was added to each well and mixed by gently agitating the plate. The cells were incubated at 37oC in 
a 5% CO2 incubator, the cell medium changed after 6 h of transfection and cells and conditioned 
media (in some experiments) were collected after 24h of total transfection time. Table 3 presents 
details on the transient transfections performed in each assay.  
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Table 3. Cell transient transfection conditions adopted for each procedure.  
Assay/cell line Transfected cDNAs 
Quantity (µg)/plate 
(mm) 
CD81 expression 
CHO and SH-SY5Y cells 
mApple-CD81 
pCDM8 hCD81 
0,5; 1.0; 1,5; 2.0 / 32 
mm plated 
GFP-Trap and RFP-Trap 
CHO cells 
GFP/mApple 
APP-GFP/mApple 
APP-GFP/mApple-CD81 
GFP/mApple-CD81 
1.0 µg +1.0 µg (co-
transfection)  / 32 mm 
Co-Immunoprecipitation of CD81 
CHO cells 
mApple-CD81 12 µg/ 100 mm plates 
Co-Immunoprecipitation of 
APP and CD81 
SH-SY5Y cells 
APP pRC/CMV 
pCDM8 hCD81 
APP pRC/CMV/ pCDM8 hCD81 
pRC/CMV /pCDM8 
12 µg (single 
transfection) 
6 µg +6 µg (co- 
transfection) / 100 mm  
 
3.3. Antibodies 
Several primary antibodies were used in this study. Since it was the first time that in our 
group that we work with CD81 protein, we performed an optimization of the primary antibodies 
used against this protein (see section 4.2.3).  
The primary antibodies used for immunoblotting assays were the rabbit monoclonal 
antibody EPR4244 (Abcam) against CD81 aa 150-250, which enables to detect the endogenous and 
exogenous CD81; the rabbit polyclonal antibody ab28664 (Abcam) against Red Fluorescent Protein 
(RFP), for detecting mApple-CD81; and mouse monoclonal anti-APP 22C11 (Chemicon) against the 
APP N-terminus aa 60-100, which enabled the evaluation of endogenous and exogenous APP and 
to measure the levels of total sAPP (α and β) in the conditioned medium.  To analyse the effects of 
CD81 overexpression in cytoskeleton-related proteins, mouse monoclonal anti-Acetylated Tubulin 
(Sigma-Aldrich) and anti-β-actin (Novus Biologicals) antibodies were used. All the secondary 
antibodies, either recognizing mouse or rabbit antibodies were goat antibodies labelled with 
horseradish peroxidase (HRP), purchased from GE Healthcare. 
For co-immunoprecipitation assays, the mouse monoclonal antibody 1D6 (Abcam) was 
used to immunoprecipitate the CD81 protein, and the anti-APP 22C11 was used to 
imunoprecipitate the APP protein.  
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In the immunocytochemistry assays, the following antibodies were used: the monoclonal 
antibody M38 (Abcam) against CD81, to analyse the location of CD81 in cells; the rabbit polyclonal 
anti-APP CT695 (Invitrogen), direct against APP C-terminus (last 50 aa); the rabbit monoclonal anti-
AKT1 (Cell Signalling). Of note, Alexa Fluor 568 Phalloidin (Life Technologies), a drug that specifically 
targets filamentous actin (F-actin) was also used in the co-localization studies. Regarding the ICC in 
sperm cells, the rabbit anti-phosphotyrosine (Invitrogene) was used to evaluate the sperm 
capacitation, and Pisum sativum agglutinin- an acrosome content marker- coupled with fluorescein 
isothiocynate (PSA-FICT, Sigma) was used to access acrosomal integrity. The secondary antibodies 
used in ICC assays were Alexa Fluor 594 goat anti-mouse and anti-rabbit, and Alexa Fluor 488 goat 
anti-mouse and anti-rabbit (Life Technologies). Table 4 summarized the different antibodies and 
their dilutions used in all this work. 
Table 4. Summary of the primary and secondary antibodies, and their specific dilutions, used to probe the 
target proteins in the different assays.  
Target protein 
Primary antibodies Secondary  antibodies 
Assay/Dilution Assay/Dilution 
CD81  
M38  
ICC dilution: 1:100 
Alexa Fluor 594 goat anti-mouse IgG  
ICC: 1:300 
1D6 
IP: 8 µg 
N/A 
EPR4244 
WB: 1:1000  
HRP conjugated anti-rabbit IgG 
WB: 1:2500 
APP 
22C11  
IB: 1:250  
WB: 25 µl 
HRP conjugated anti-mouse IgG 
WB: 1:5000 
CT695 
ICC: 1:100  
Alexa Fluor 488 goat anti-rabbit IgG  
ICC: 1:300 
RFP 
ab28664 
WB: 1:1000 
HRP conjugated anti-rabbit IgG 
WB: 1:5000 
Phosphotyrosine ICC: 1:10 
Alexa Fluor 488 goat anti-rabbit IgG  
ICC: 1:300 
Acetylated 
Tubulin  
clone 6-11B-1 
WB: 1:2000 
HRP conjugated anti-mouse IgG 
WB: 1:5000 
 
β- actin 
 
WB: 1:10000 
HRP conjugated anti-mouse IgG 
WB: 1:5000 
AKT ICC: 1:200 
Alexa Fluor 488 goat anti-rabbit IgG  
Alexa Fluor 594 goat anti-rabbit IgG  
ICC: 1:300 
Abbreviations: APP, Amyloid precursor protein; AKT, RAC-alpha serine/threonine-protein kinase; ICC, 
immunocytochemistry; IP, immunoprecipitation; RFP, Red Fluorescent Protein; WB, Western blot 
DCM/UA 2015 
 
CD81 interacting proteins    31 
  
3.4 Proteomic assays 
 
Cell´s conditioned media were collected with 1/10 v/v 10% SDS, and cells washed with PBS 
and harvested in 250 µl (6-well) , 750 µl (100 mm) or 500 µl (42x106 sperm cells)  of 1% SDS for WB. 
Cells and media lysates were boiled at 90oC for 10 min and cell lysates sonicated for 10 sec; both 
were stored at -20 oC. The cell collection procedure for the pull-down assays is slightly different and 
is described further ahead.  
 Total protein content of cell lysates was carried out using the Pierce’s bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific), following the manufacturer’s instruction. This method 
combines the reduction of Cu2+ to Cu+ by protein in an alkaline environment with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu+) by bicinchoninic acid. The 
result of this two reactions is the formation of an intense purple-coloured reaction product, a 
water-soluble complex with a strong absorbance at 562 nm with increasing protein concentrations 
over a working range of 20-2000 µg/ml82. Total protein concentration of each sample was 
determined by comparision to standard samples that were prepared using increasing known 
amounts of bovine serum albumin (BSA).  
An aliquot of cell lysates samples (5 µl) was diluted with 20 µl of 1% SDS in a 96 well plate, 
and these aliquots incubated at 37oC for 30 min with 200 µl of working reagent (compound of 50 
parts of reagent A to 1 part of reagent B), alongside with BSA protein standards (both in duplicate).  
Following, the absorbance at 562 nm was measured with the Infinite M200 microplate reader. A 
standard curve was obtained by plotting BSA vs BSA concentration, and used to determine the total 
protein concentration of each sample.  
 
 
In order to determine if APP and CD81 physically interact, we performed co-
immunoprecipitation (Co-IP) assays. These are an extension of immunoprecipitation (IP) that is 
based on the potential of IP reactions to capture and purify the primary target protein as well as 
other proteins that are bound to the primary target by native interactions. In our experimental 
procedure, the Co-IP was carried out using Protein G Dynabeads® (Invitrogen). The procedure is 
based on the ability of Protein G Dynabeads® to bind to the Fc region of primary antibodies. The 
immune complex is then precipitated on a beaded support to which an antibody-binding protein is 
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immobilized. The tube is placed on a magnet, where the beads migrate to the side of the tube facing 
the magnet and allow for easy removal of the supernatant. Proteins not precipitated on the beads 
are hence washed away83.  
The co-IP assays of CD81 were performed in CHO and SH-SY5Y grown in 100 mm culture 
dishes (section 3.3.1). Following 24 h of transient transfection with the CD81 and/or APP cDNAs 
(section 3.2.2), media were removed and cells washed with cold PBS 1x and then gently scrapped 
off the culture plate with 750 μl of non-denaturing lysis buffer. CHO cells were collected in NP-40 
lysis buffer [10 mM Tris-HCl pH 7.5; 150 mM NaCl, 0.5 mM EDTA, 1%NP-40, 1mM PMSF and 
protease inhibitor cocktail (0.1%, Sigma-Aldrich)]. SH-SY5Y cells were collected in CHAPS lysis buffer 
[50 mM Tris-HCl pH 8.0, 120 nM NaCl, 4% CHAPS, 1mM PMSF and protease inhibitor cocktail]. 
Lysates were mass-normalized using the BCA assay (section 3.4.1) and 1000 μg of each lysate 
precleared with 15 μl Dynabeads for 1 hour at 4°C with agitation. In a separate microtube, 40 μL of 
Dynabeads were added to 200 μl of Washing solution (3% BSA in PBS) containing the primary 
antibody (APP or CD81 at respective dilutions, depicted in Table 4) for 1 hour at 4°C with agitation. 
Prior to use, Dynabeads were washed thrice with Washing Solution and stored at 4°C. 
After 1 h, each sample was transferred to the antibody/Dynabeads-containing microtube, 
previously washed with 200 μl of washing solution, and incubated overnight at 4°C with agitation. 
Following, the supernatant was removed and the beads washed thrice with 500 μl of PBS 1x for 10 
min at 4°C with agitation. After the last wash, the supernatant was fully discarded and the beads 
resuspended in 100 μl of 1x Loading Buffer (LB) and boiled for 10 min at 90°C for disruption of the 
Dynabead-proteins complex. Dynabeads were magnetically removed, and lysates and 
immunoprecipitates further resolved in a 5-20% gradient SDS-PAGE followed by immunoblotting, 
as described in section 3.4.4. Co-IP controls were performed by incubating cell extracts with 
Dynabeads linked to Normal Mouse IgGs (Santa Cruz Biotechnologies).  
 
 
Another approach used to study the interaction between APP and CD81 was to pull-down 
these proteins when fused to GFP and mApple (RFP derivated) proteins.RFP and GFP-fusion 
proteins and their binding partners can be fast and efficiently isolated via pull-down of the RFP with 
RFP-Trap® (Chromotek) and GFP with GFP-Trap® (Chromotek). After CHO cells transient 
transfection for 24 h with APP-GFP and mApple-CD81 cDNAs (as in section 3.2.2), cells were washed 
with 1x PBS and subsequently collected with a scrapper in 1 ml of cold PBS with 1x PMSF solution. 
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Samples were then centrifuged for 5 min at 3000 g (4oC), the supernatant removed and 500 µl of 
freshly prepared Triton-X lysis buffer (10 mM Tris-HCl pH 7.5;  150 mM NaCl, 0.5 mM EDTA, 1% 
Triton-X, 1mM PMSF and 0,1% protease inhibitor cocktail were added to the pellet. Samples were 
maintained on ice for 30 min and mixed twice, with 10 min intervals. Meanwhile, the RFP-Trap or 
GFP-Trap beads were washed 4 times in freshly prepared wash buffer, isolated by a magnet and 
kept at 4oC. After lysis, the samples were centrifuged for 5 min at 10000 g (4oC), and the supernatant 
transferred to a new microtube. Mass normalized (150 μg/sample) were adjusted to 300 μl with 
freshly prepared dilution buffer, and 10 μl of the RFP-Trap or GFP-Trap beads added to each sample 
and incubated for 4 h with orbital shaking at 4oC. Following the incubation period, the supernatant 
was removed and the beads washed thrice with 300 μl of wash buffer. After the last wash, the 
supernatant was fully discarded and the beads resuspended in 100 μL of 1x Loading Buffer and 
boiled for 10 min at 90°C for disruption of the trap beads proteins complexes. Trap beads were 
removed, and lysates and immunoprecipitates were then resolved in a 5-20% gradient SDS-PAGE 
followed by immunoblotting as described in section 3.4.4.   
 
 
Western-blot (WB) or immunoblot (IB) is a rapid and sensitive assay used in cellular and 
molecular biology for the identification and quantification of specific proteins from a complex 
mixture of proteins. The technique uses three elements: 1) separation by size; 2) transfer to a solid 
support and 3) probing a target protein with a proper primary and secondary antibody, linked to an 
enzyme or fluorophore to visualize84.   
In the present work, mass-normalized samples were resolved by electrophoresis on a 5-
20% gradient sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE), a 
denaturing gel that allows for the separation of proteins solely on the basis of their molecular 
weight. It consists of two gels: a resolving (bottom) gel, with higher concentration of polyacrylamide 
to separate proteins, and a stacking (top) gel, with lower concentration of polyacrylamide and high 
concentration of SDS, which confers negative charge for the proteins to migrate to the anode.  
Prior to loading, the samples were prepared by the addition of ¼ volume of loading buffer 
(4x), which consists of glycerol, SDS, a reducing agent (β-mercaptoethanol) and a dye (bromophenol 
blue). Electrical current is then applied to the gel (90 mA) enabling the separation of proteins. 
Precision plus Protein ™ Dual Colour Standards (Bio Rad) was used as a molecular weight marker. 
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After separation, the proteins were electrotransferred at 200 mA onto a nitrocellulose membrane 
(0.2 µm pore size; Whatman®).  
 
Ponceau Red staining is normally applied to assess successful electrotransfer of proteins to 
the membrane, but it can be also used as a loading control as an alternative to actin or β-tubulin 
when the levels of these proteins may change with the conditions under test. This type of staining 
has been described as a fast, inexpensive, and nontoxic method, and it is fully reversible in a few 
minutes85. The nitrocellulose membrane were incubated in Ponceau S Solution (Sigma Aldrich) for 
10 min, followed by a wash with deionized water for making the protein bands clearly visible. 
Membranes were then scanned in a GS-800 calibrated imaging densitometer (Bio-Rad), after which 
membranes were washed with 1x TBS-T for complete removal of the staining.  
 
Concerning the immunological detection, briefly, the nitrocellulose membranes were first 
hydrated in 1x TBS for 10 min and then blocked with 5% BSA in Tris Buffered Saline Tween (TBS-T) 
1x for 4 h. Membranes were then washed in TBS-T 1x for 10 min, incubated with a specific primary 
antibody (depicted in Table 4) overnight, washed thrice with TBS-T 1x for 10 min each, incubated 
with the appropriate HRP-conjugated secondary antibody for 2 h and washed thrice with TBS-T 1x 
for 10 min. Following, membranes were incubated with enhanced chemiluminescence (ECL) 
detection kit for 1 min, with Luminata™ Crescendo Western HRP Substrate (Millipore) or with 
ECL™ Select WB detection reagent (GE Healthcare) for 5 min, in a dark room. After exposure of the 
membranes to X-ray films (GE Healthcare), these were developed and fixed with the appropriate 
solutions (Kodak). Films were then scanned in the GS-800 calibrated imaging densitometer (Bio-
Rad) and the results analysed. 
 
3.5 Immunocytochemistry (ICC) assays 
To determine if APP and CD81 co-localize in mammalian cells and their sub cellular 
localization, immunocytochemistry (ICC) assays were performed in CHO, GC-1 and SH-SY5Y cell 
lines, as well as in sperm cells.  
ICC is a technique that permits the visualization of the localization of a specific protein, 
thought protein-antibody interactions, in fixed cells86. 
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Initially, samples are prepared by fixing with a fixation agent such as paraformaldehyde 
(PFA), which helps to stabilize and preserve cells as close to life-like as possible. This occurs by 
binding of the agent to reactive groups on cellular proteins and lipids, what holds them in the same 
position as if they were in living cells. Fixed cells are then permeabilized, so that antibodies and 
other probes can penetrate inside. This is achieved by the addition of detergents, which can 
solubilize membranes without destroying protein-protein interactions. Following permeabilization, 
non-specific binding sites in cells are blocked, incubated with the proper specific antibody primary 
and fluorescent secondary antibodies, and mounted on a microscope slide in a media with anti-
fading and anti-photobleaching properties. The preparation can be further visualized through a 
fluorescent microscope86. The excitation and emission wavelengths peaks of the secondary 
antibodies, fluorescent tags and PSA-TRICT are presented in table 5.  
 
Table 5. Summary of the excitation and emission wavelengths of the secondary antibodies, fluorescent tags 
and PSA-TRICT. 
 
 
 
In the present work, the cell culture was performed as described in section 3.2.1 in 6-well 
plates containing glass coverslips. Cells were washed (PBS 1x) and 1 ml of 4% PFA was added for 20 
min. Following fixation, cells were washed trice with PBS 1x, and 300 μl of 0.2% Triton-X was added 
for 10 min. After another 3 washes with 1x PBS, cells were covered with 1x PBS/3% BSA blockage 
solution for 30 min, followed by 2 h incubation with the specific antibodies diluted in 1x PBS/3%BSA, 
washed with 1x PBS, and further incubated for 1 h with a fluorescent secondary antibody (Table 4). 
Fluorophores 
Excitation maximum 
(nm) 
Emission maximum 
(nm) 
Observed 
colour 
Alexa Fluor 488 495 519 Green 
Alexa Fluor 594 590 617 Red 
mApple Tag 568 592 Red 
GFP Tag 488 507 Green 
PSA-FITC 495 515 Green 
Alexa Fluor 568 
Phalloidin 
578 600 Red 
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Samples were then mounted on a microscope slide with DAPI-containing VECTASHIELD® Mounting 
Media (Vector Laboratories) and visualized using a LSM510-Meta confocal microscope (Zeiss) with 
the 63x/1.4 or 100x/1.4 oil immersion objectives. The 405 nm argon diode laser, the argon laser 
line 488 nm, and the 561 nm DPSS laser were used.  
 
Capacitated and acrosome reacted sperm cells were fixed with 2% formaldehyde in PBS for 
40 min, washed with PBS, and permeabilized with 1% Triton X-100 in PBS for 20 min. After washing 
with PBS, sperm cells were blocked with 1% BSA and 100 mmol/L glycine in PBS for 30 min. After 
blocking, 100 µl of sperm cells were incubated for 2 h at 37oC with the respective primary antibody 
(Table 4). Sperm cells were subsequently washed with 300 µl of washing solution (0,1% Triton X-
100 in PBS) for 30 min. Sperm cells were then incubated 1 h at 37oC with the respective secondary 
antibody and acrosome reacted sperms were also incubated with PSA-FITC (1:200). Sperm cells 
were washed with 300 µl of washing solution for 15 min. Among washing steps, sperm cells were 
centrifuged at 1800 rpm/ 5 min. Samples were mounted on a microscope slide with DAPI-containing 
VECTASHIELD® Mounting Media and visualized using the LSM510-Meta confocal microscope under 
a 100x/1.4 oil immersion objective, and using the lasers above identified. Sperm cells stained in the 
entire tail were considered capacitated; those with a negative staining for PSA-FITC were 
considered acrosome-reacted.   
 
3.6 Data Analysis 
The protein bands resultant from the WB procedures were quantified using Image Lab 
Software (Bio-Rad) and data presented as mean ± SEM (standard error of the mean) of at least 
three different experiments.  
 
3.7 Micropotographs analysis 
Image analysis was performed using the ImageJ Fiji software87. The co-localization analysis 
was conducted using the JACoP (‘Just another colocalization Plugin’). This plugin uses several pixel 
intensity spatial correlation methods to determine co-localization between two different colour 
channels, such as the Manders, the Costes, the Pearson or the Li methods. In the work here 
DCM/UA 2015 
 
CD81 interacting proteins    37 
  
described, results were obtained using the Manders' method, since it is normally the most used 
method when comparing two objects of different amounts (in this case two proteins which most 
probably have different expression levels)88.  Co-localization of APP and CD81 was analyzed using 
~20 images with an average of 10 cells per image. The results are presented as the percentage of 
co-localization of one protein with the other.  
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 Results  
4.1  Bioinformatics analyses of CD81 interacting proteins 
A major difficulty in the study of tetraspanins is to determine functions that are specific to a 
given tetraspanin; however, specific tetraspanin-associated proteins may help to clarify this issue. 
The spatial organization of membrane proteins in the plasma membrane is critical for signal 
transduction, cell communication and membrane trafficking. As mentioned earlier, tetraspanins are 
organized functionally in protein complexes called TEM via interactions with partner proteins and 
other tetraspanins. Considering the large tissue distribution of CD81, this tetraspanin protein has 
been implicated in a large number of biological processes. However its specific function in these 
processes remain to be elucidated. The interaction between CD81 and certain partner proteins may 
underlie the CD81 involvement in a variety of cellular processes and modulate CD81/partner 
proteins specific functions40,89.  
To better understand the physiological role of CD81, a search for the available CD81 interacting 
proteins was performed in databases and in the literature. The retrieved information was then 
further investigated by constructing a protein-protein interaction (PPI) network, and by performing 
Gene Ontology (GO) term enrichment analysis for functional interpretation of the interacting 
proteins, and by performing a pathway analysis though various computational tools.  
 
 
Identification of literature curated interactions 
In order to identify the interactors of CD81, human PPIs were collected from the public 
database Biological General Repository for Interaction Dataset (BioGrid)78. During the literature 
research performed for this current work, many CD81 interacting proteins were identified. Since 
some of these interactions were not included in the BioGrid database, the interactions that were 
elsewhere identified, namely in articles retrieved from PubMed, were manually included.  
A total of 222 proteins were identified as CD81 interacting proteins, among which 196 
proteins were retrieved from BioGrid and 26 were identified in the literature. Only interactions that 
were curated have been used. A full list of the CD81 interacting proteins is presented in Table 1 
(Appendix 1).  
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Construction of CD81 protein interaction network 
All collected proteins were loaded into GeneMANIA79 to construct a CD81 protein 
interaction network. The network was generated using physical interactions and “Biological process 
based” as the network weighting method. From the total of 222 genes used as input, 219 ID were 
recognized. GeneMANIA introduced 20 genes, as genes that are functionally similar, or have shared 
properties with CD81 interactors. The extracted network (Figure 14) consists of 239 protein nodes 
and 2632 interactions between these proteins. The full list of proteins with the associated scores 
extracted from this network are presented in Table 2 (Appendix 1).   
 
Figure 14. CD81 protein interaction network .This protein interaction network consists of 239 protein nodes 
and 2632 interactions Black nodes correspond to the query proteins and grey nodes corresponds to proteins 
that were added by GeneMANIA.   
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Compared with the affluence of cell-surface molecules that associated with tetraspanins, 
only a few cytoplasmic molecules have been shown to interact with tetraspanins90. In contrast with 
this data, the analysis of CD81 interacting network showed that the majority of proteins were 
located in the cytoplasm and nucleus. 
 
 
A GO-term enrichment analysis was used to compare the abundance of specific GO-terms 
in the CD81 interacting network with the natural abundance in the organism in question (Homo 
sapiens). 
The proteins identified in the present study that interact with CD81 were analysed using 
PANTHER - Protein Analysis Through Evolutionary Relationships80 according to GO annotation by 
grouping them into 3 categories: biological processes, molecular functions and cellular 
components. Not all the protein entries were fully annotated with the corresponding GO terms but 
from the total of 222 proteins entries, 214 were categorized using the “statistical 
overrepresentation test” analysis. The statistical method using the Bonferroni correction was 
applied and only GO terms with a p-value < 0.05 were considered. 
Regarding the biological process (Table 6), the results revealed that the categories with the 
largest number of proteins were related to: metabolic processes (56%; p-value = 4.02E-09), primary 
metabolic processes (53%; p-value = 1.09E-12), cellular processes (41%; p-value = 4.87E-03), protein 
metabolic process (33%; p-value = 7.43E-15), and protein translation (22%; p-value = 7.33E-34). 25 
proteins were not classified (12%; p-value = 0).  
Table 6. Significantly enriched gene ontology categories by biological process of gene products interacting 
with CD81. p-value < 0.05.  “% ID” indicates the percentage of proteins associated with each GO term relative 
to the total number of proteins that were categorized. 
Most Significant Biological process 
GO term 
% 
ID 
p-value GO term 
% 
ID 
p-value 
Translation 22 7.33E-34 Chromatin organization 8 4.99E-09 
Protein metabolic process 33 7.43E-15 
Anatomical structure 
morphogenesis 
11 2.84E-07 
Chromatin assembly 5 1.69E-13 Intracellular protein transport 13 7.32E-05 
Primary metabolic process 53 1.09E-12 Protein transport 13 1.28E-04 
mRNA splicing, via spliceosome 9 2.42E-12 Organelle organization 9 2.89E-04 
mRNA processing 10 3.05E-12 Nuclear transport 4 2.96E-04 
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Most Significant Biological process 
Cellular component 
organization or biogenesis 
21 7.34E-12 
Cellular component 
morphogenesis 
8 4.48E-04 
Regulation of translation 8 1.30E-11 DNA metabolic process 7 5.13E-04 
RNA splicing, via 
transesterification reactions 
7 3.27E-11 
Nucleobase-containing 
compound metabolic process 
26 1.26E-03 
RNA splicing 7 4.57E-11 Cellular process 41 4.87E-03 
Cellular component biogenesis 10 3.07E-10 Cell cycle 12 5.52E-03 
Cellular component 
organization 
18 3.32E-09 Developmental process 19 3.44E-02 
Metabolic process 56 4.02E-09 Chromosome segregation 3 4.43E-02 
 
Regarding molecular function (Table 7), results show that the majority of proteins are 
involved in binding processes (53%; p-value = 1.01E-12), more specifically nucleic acid binding (40%; 
p-value = 3.29E-18), RNA binding (19%; p-value = 5.85E-23), and structural molecular activity (27%; 
p-value = 5.85E-23). This category contains 49 unclassified protein (23%; p-value = 0). When 
proteins are categorized according to their cellular component (Table 7), most of the proteins are 
considered intracellular (28%; p-value = 2.58E-08), located in macromolecular complexes (23%; p-
value = 3.06E-21), organelle (19%; p-value = 2.43E-04) and ribonucleoprotein complexes (8%; p-
value = 7.27E-12). However, in this category a high number of proteins were not classified (66%; p-
value = 0) 
Table 7. Significantly enriched gene ontology categories by cellular component and molecular function of 
gene products interacting with CD81. p-value < 0,05. “% ID” indicates the percentage of proteins associated 
with each GO term relative to the total number of proteins that were categorized.  
Most Significant Molecular Function Most Significant Cellular component 
GO term 
% 
ID 
p-value GO term 
% 
ID 
p-value 
Structural molecule activity 27 5.85E-23 Macromolecular complex 23 3.06E-21 
RNA binding 19 5.85E-23 Protein-DNA complex 5 5.37E-13 
Nucleic acid binding 40 3.29E-18 Ribonucleoprotein complex 8 7.27E-12 
Structural constituent of 
ribosome 
11 5.52E-16 Nuclear chromosome 5 1.83E-09 
Translation factor activity, 
nucleic acid binding 
9 1.06E-13 Chromosome 5 2.31E-08 
Binding 53 1.01E-12 Intracellular 28 2.58E-08 
Translation regulator activity 7 1.17E-10 Tubulin complex 3 1.94E-07 
Translation initiation factor 
activity 
7 5.06E-10 Cell part 30 3.00E-07 
mRNA binding 7 7.02E-08 Ribosome 4 3.24E-07 
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Most Significant Molecular Function Most Significant Cellular component 
Structural constituent of 
cytoskeleton 
12 5.05E-06 Cytosol 3 3.97E-05 
RNA helicase activity 3 4.18E-03 Organelle 19 2.43E-04 
Helicase activity 4 1.02E-02 Nucleus 6 6.38E-04 
Translation elongation factor 
activity 
   2 2.17E-02 Protein complex 9 1.56E-03 
 
The analysis of enriched GO categories showed that, regarding their biological processes, 
most proteins that interact with CD81 are mainly involved in the determination of DNA and RNA 
fate, including RNA splicing and translation, or in cell metabolism. To achieve these processes, the 
result of the analysis of molecular functions suggests that the majority of proteins are involved in 
nucleic acid/RNA/mRNA binding and binding to molecules involved in Protein Translation. Some of 
these are proteins with an active role in the regulation of translation once they act as initiation and 
elongation factors. Regarding the cellular component, as expected from their molecular functions, 
most proteins were located in the cytosol and nucleus, more specifically in ribosomes and 
chromosomes. 
 
 
Similar to GO term enrichment analysis, an analysis of pathway abundance was performed. 
This analysis might be more meaningful since it moves the data interpretation away from a gene-
centric view towards the identification of common functional biological processes 91.  
Cell-signalling pathways were analysed using PANTHER. A PANTHER overrepresentation 
test analysis was performed, and from the total of 222 proteins entries, 214 were categorized. Table 
8 presents the signalling pathways in which some of the CD81 interacting proteins are involved. The 
top 5 significant pathways were: cytoskeletal regulation by Rho GTPase (p-value = 3.48E-11); 
Huntington’s disease (p-value = 2.11E-08); integrin signalling pathway (p-value = 2.22E-05); 
Gonadotropin releasing hormone receptor (p-value = 6.08E-04) and Alzheimer’s disease-amyloid 
secretase pathway (p-value = 6.17E-04). It is important to note that 166 proteins were not classified 
using this approach. From the proteins that were classified, AKT1, RAC1, RAC2, and proteins of the 
Tubulin beta family are interesting CD81 interacting proteins that play a key role in various CD81 
pathways. Further, from the 24 pathways identified, two are related to the APP proteolytic 
processing. 
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Table 8. Significant signalling pathways in which gene products interacting with CD81 are involved. p-value < 
0.05. 
Pathways Gene ID p-value 
Cytoskeletal regulation by Rho GTPase 
TUBB4B, TUBB3, CLF1, RPL12, TUBB6, 
TUBB2B, TUBB, ACTB, RAC1, CFL2, RAC2 
3.48E-11 
Huntington disease 
TUBB4B, TUBB3, RPL12, TUBB6, TUBB2B, 
TUBB, TUBB2A, AKT1, GAPDH, TUBB4B, 
ACTB, RAC1, RAC2 
2.11E-08 
Integrin signalling pathway 
ITB1, RAC1, ACTB, ITGA4, ACTN1, FLNA, 
ACTN4, HRAS, SHC1, RAC2 
2.22E-05 
Unclassified 166 IDs 2.55E-05 
Gonadotropin releasing hormone receptor 
pathway 
ITGB1, GNAQ, AKT1, RAC1, TUBA1B, GNA11, 
HRAS, TUBA1C, TUBA1A 
6.08E-04 
Alzheimer’s disease-amyloid secretase 
pathway 
PKN1, APP, PSEN1, PSEN2, ADAM10 6.17E-04 
Inflammation mediated by chemokine and 
cytokine signalling pathway 
ITGB1, ATP50, GNAQ, AKT1, RAC1, ACTB, 
ITGA4, GNA11, SHC1 
1.10E-03 
Ras Pathway AKT1, RAC1, HRAS, SHC1, RAC2 1.46E-03 
T cell activation AKT1, RAC1, HRAS, CD74, RAC2 1.54E-03 
PI3 kinase pathway GNAQ, AKT1, GNA11, HRAS 1.76E-03 
VEGF signalling pathway AKT1, RAC1, HRAS, RAC2 3.42E-03 
B cell activation CD19, RAC1, HRAS, RAC2 4.81E-03 
p38 MAPK pathway TRAF6, RAC1, RAC2 7.90E-03 
CCKR signalling map ITGB1, RPS6, TRAF6, AKT1, RAC1, SHC1 8.54E-03 
FGF signalling pathway AKT1, RAC1, HRAS, SHC1, RAC2 9.31E-03 
EGF receptor signalling pathway AKT1, RAC1, HRAS, SHC1, RAC2 1.16E-02 
Muscarinic acetylcholine receptor 1 and 3 
signalling pathway 
GNAQ, PKN1, GNA11 1.53E-02 
Axon guidance mediated by semaphorins RAC1, RAC2 2.20E-02 
Glycolysis GAPDH, PKM 2.58E-02 
Axon guidance mediated by Slit/Robo RAC1, RAC2 2.58E-02 
Histamine H1 receptor mediated signalling 
pathway 
GNAQ, GNA11 3.64E-02 
Alzheimer’s disease-presenilin pathway APP, PSEN1, ACTB, PSEN2 3.82E-02 
Metabotropic glutamate receptor group I 
pathway 
GNAQ, GNA11 4.35E-02 
Corticotropin releasing factor receptor 
signalling pathway 
GNAQ, GNA11 4.59E-02 
Axon guidance mediated by netrin RAC1, RAC2 4.84E-02 
 
Tetraspanins are linked to intracellular signalling components suggesting that they mediate 
the cross-talk between cell surface stimuli and intracellular signalling pathways38. Regarding the 
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pathway analysis, it seems that some of the CD81 interactors are involved in cytoskeletal regulation 
by Rho GTPase, a typical small GTPase that is the representative of its family that bind actin and 
regulated its polymerization into Filamentous actin (F-actin).  
Another significant pathway regulated by CD81 is the Integrin signalling pathway, which is 
triggered when integrins in the cell membrane bind to extracellular matrix components80. Integrin 
proteins also bind actin, and are mainly involved in cell-cell adhesion and cell-substrate adhesion 
processes, being therefore key regulators of cell migration and cellular differentiation.  
The analysis of pathways also revealed two pathways that are related to the proteolytic 
cleavage of APP.  As depicted in chapter 1.3.2, APP can be processed to yield the Aβ peptide, a 
triggering factor in Alzheimer’s disease. To produce this peptide, full-length APP is first cleaved by 
β-secretase, into a fragment that is further cleaved by γ-secretase. Alternatively, full-length APP 
can be cleaved by α-secretase, releasing a soluble fragment (sAPPα) with neuroprotective 
properties. CD81 can participate in both pathways since it interacts with ADAM10 (α-secretase), 
with Presinilins PS1 and PS2 (γ-secretase) and with APP itself92–94. This last interaction was proved 
to occur in neurons, more specifically in axonal growth cones, but its functional relevance was not 
clarified since the aim of that work was to study CD81 interaction with laminin99. CD81 physically 
interacts with ADAM10, and CD81 expression in MCF7 and SH-SY5Y cells promotes ADAM-10-
dependent APP proteolysis92. On the other hand, Wakabayashi and colleagues (2013)93 showed that 
the interaction between CD81 and  PS1 or PS2 modulated the γ-secretase APP processing.  
In synthesis, through the interaction with a large number of molecular partners, CD81 can 
induce intracellular signalling that is required for functional effects such as cell adhesion, migration 
and proliferation, and it can also influence the proteolytic cleavage of proteins such as APP.   
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4.2 Optimization of cellular and molecular tools 
 
Cellular growth curves are applied in the evaluation of growth characteristics such as 
population doubling time, lag time, and saturation density. After re-seeding cells present a ‘lag-
phase” that can take from a few hours up to 48 h, a period of time required for a cell to recover 
from trypsinization, to rebuild its cytoskeleton, and to secret an extracellular matrix that facilitates 
cell-substrate adhesion and their propagation along the substrate. Subsequently, the cells enter 
into an exponential growth termed the ‘log-phase’ that lasts until the entire growth surface is 
occupied, or the cell concentration exceeds the capacity of the substrates in the growth medium. 
When the cell proliferation slows and stops, the cellular population enter in a ‘stationary phase’. 
Finally, if the culture medium in not replaced and the cell number is not reduced, the cells lose 
viability and their number decreases, entering a ‘decline phase’. This mean that cells in culture need 
to be subcultured on a regular basis before they enter in the stationary growth phase95,96. 
In order to determine the growth characteristics of the CHO cell line, a growth curve was 
performed, as described previously (section 3.3.3), using two different methods to measure cell 
viability. One involves the use of Trypan Blue (TB), which penetrates dead cell membrane and gives 
them a characteristic blue colour, whereas the living cells are not permeable to TB and remained 
uncoloured. This method has some advantages over spectrophotometric measurements because it 
can be very sensitive for conditions of only a few number of cells, and allows the observation of the 
cell morphology and the detection of culture contaminants96. The second method used was the 
resazurin metabolic assay. This assay served as an effective tool for assessing cell viability and cell 
proliferation because it is one-step, sensitive, safe, non-toxic for cells, and cost-effective. The 
resazurin is a blue indicator dye that enters inside the cell and undergoes enzymatic reduction in 
mitochondria due to the activity of NADH. The product of its reduction, resofurin, is excreted 
outside cells into the growth medium, which results in a visible medium colour change from blue 
to pink. The rate of reduction, and thus the colour change, reflects the number of viable cells97. 
Figure 15 shows the growth curves for CHO cells, as determined by the Trypan blue and Resazurin 
metabolic assays. 
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The CHO cells manifested the expected four phases of cell growth. After 2-3 days of 
incubation, cells left the lag phase and the cellular growth began an exponential phase (Figure 15). 
Cells reached the stationary phase after 8-9 days of subculture, and entered in a decline phase 
where the number of cells started to decrease after 10 days of subculture. This behaviour was 
better observed with the Trypan blue method, as the Resazurin assay failed particularly at the end 
of the log phase and during the stationary and decline phase. For example, according to the growth 
curve determined by this method, after 8 days of subculture the number of viable cells were still 
increasing, which not did reflect the real number of viable cells. This method is thus preferentially 
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used for cells in the exponential phase, fact that can be observed in Figure 16. When CHO cells 
exceed the ~2.4x105 number, resazurin assay was no longer sensible. Hence, for a higher number 
of cells, the conditions (resazurin concentration and time of incubation) of this method should be 
optimized.  
 
 
 
These growth curves allow to determinate the population doubling time (DT). According to 
ATCC®, the population DT is the time required for a culture to double in number, and is calculated 
using the following formula, where T is the incubation time (any units), Xb is the cell number at the 
beginning of the incubation, and Xe is the cell number at the end of incubation)98: 
𝐷𝑇 =
T ln2
ln (
Xe
Xb)
 
To ensure viability, genetic stability and phenotypic stability, a cell line needs to be 
maintained in the exponential phase, and the DT should be calculated in this phase. The 
experimentally determined DT of CHO cells was of 25h32.  
The determination of the growth curve of CHO cells permitted a better maintenance and 
handling of these cells in culture, previously and during the assays performed in this study.  
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Before performing a routine transfection procedure, a critical first step is to optimize 
conditions. This optimization is not just about getting cells to take up as much DNA as possible. It is 
about finding the optimal balance between maximal protein expression and minimal impact on cell 
viability. Different amounts of CD81 and APP cDNAs were first tested (Table 9) in order to choose 
the ones to use throughout the experiments. Cells were seeded in a 6-well plates before 
transfection and then transfected with different cDNAs for 24 h using the TurboFect™ reagent.  
 
Transient transfection of CD81 constructs: mApple-CD81 and pCDM8 hCD81 
To optimize the transient transfection of CHO cells with CD81 cDNAs, these were transfected 
with 0.5; 1.0; 1.5 and 2.0 µg of mApple-CD81 and pCDM8 hCD81 cDNAs. The transfection efficiency 
was evaluated by:  1) WB using an anti-RFP or the anti-CD81 EPR4244 antibody and 2) by ICC; since 
the mApple tag is fluorescent, the anti-CD81 antibodies were only used for the detection of cells 
transfected with pCDM8 hCD81. WB results for the transfection efficiency of CHO cells are 
presented in Figure 17, and ICC data in Figure 18. When mApple-CD81 was transfected, the 
expected band corresponding to the CD81 protein fused to mApple tag was detected at ~44 kDa 
(Figure 17a, arrow). pCDM8 hCD81 expression increased the pool of endogenous CD81, detected 
at ~24 kDa (Figure 17b) 
 
  
 
 
 
 
 Figure 17. Efficiency of transfection of CD81 cDNA upon 24h of CHO transfection; a) WB analysis of CD81 
expression in mApple-CD81 transfected CHO cells using the anti-CD81 EPR4244 antibody. Arrow indicates 
mApple-CD81 and arrowhead indicates endogenous CD81. b) WB analysis of CD81 expression in pCDM8 
hCD81 transfected CHO cells using the anti-CD81 EPR4244 antibody  
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Figure 18. Efficiency of transfection of CD81 cDNAs upon 24 h of CHO transfection. a) Analysis of subcellular 
distribution of mApple-CD81 upon 24h of transfection with 1 and 1.5 µg of mApple-CD81. DAPI (nuclear blue 
staining) was used as a counterstaining. b) Percentage of CHO cells transfected with mApple-CD81 and 
pCDM8 hCD81 cDNAs; the number of transfected cells (red channel) and total cells (blue channel) were 
scored in various microphotographs, and the percentage of transfected cells calculated.   
  
According to the WB and ICC results, transfection with 0.5 µg of mApple-CD81 and pCDM8 
hCD81 cDNAs in CHO cells was not very efficient. Regarding the maximum of transfection, this 
occurred at 2.0 µg of cDNA for mApple-CD81 (Figure 17a and 18b) and at 1.0 µg of pCDM8 hCD81 
(Figure 18b). However, despite the results achieved with 2.0 µg of mApple-CD81, at this conditions 
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CD81 overexpression affected the cells normal behaviour and led to an increase in cellular 
apoptosis, as indicated by the presence of apoptotic nucleus in the ICC (Figure 18). For this reason 
1.0 µg of mApple-CD81 was chosen in subsequent experiments using CHO cells.  
Optimization of the transfection of mApple-CD81 in SH-SY5Y cells was also performed and 
SH-SY5Y cells transfected with 0.5; 1.0; 1.5 and 2.0 µg of mApple-CD81. The transfection efficacy 
was evaluated by scoring the percentage of cells transfected under a fluorescence microscope 
(Figure 19). As we can observe from the results, the percentage of cells transfected was higher 
when 1.0 µg of mApple-CD81 was used (~40%), suggesting that the neuronal cell-line SH-SY5Y is 
more sensitive than CHO cells to high amounts of this protein. 
 
 
 
 
 
 
 
Figure 19. Percentage of SH-SY5Y cells transfected with mApple-CD81. The number of transfected cells (red 
channel) and total cells (phase contrast brightfield) were scored in various microscope fields, and the 
percentage of the transfected cells calculated for each amount of cDNA transfected.  
 
To further analyse the pattern of transfection with mApple-CD81 in these cells, an ICC of 
cells transfected with 1.0 and 1.5 µg was performed (Figure 20). Results presented in Figure 20 
showed that mApple-CD81 is present across the cytoplasm and at the cell membrane. When 1.0 µg 
of cDNA was used, cells appeared to have increased formation of cellular projections. When 
transfected with 1.5 µg mApple-CD81, there was a clear increase in cell volume. Further, 
transfection of SH-SY5Y cells with amounts of cDNA superior than 1 µg caused cellular toxicology, 
denoted by the presence of apoptotic nucleus and higher cell death. With these results we 
concluded that the optimal amount of cDNA to use in SH-SY5Y cellular transfection is 1.0 µg of 
mApple-CD81.  
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Transient transfection of APP-GFP in CHO cells 
Since transient transfections of APP-GFP cDNAs in SH-SY5Y cells are already optimized in our 
lab (established at 1.0 µg of APP-GFP), we only performed this optimization in CHO cells. For this 
purpose, CHO cells were transiently transfected with 1.0 and 1.5 µg of APP-GFP cDNAs. The 
transfection efficiency is presented in Figure 21.  
 
 
 
 
 
 
 
 
Figure 20.  Analysis of subcellular distribution of mApple-CD81 in SH-SY5Y transfected 24h with 1.0 and 
1.5 µg of mApple-CD81 cDNAs. DAPI (nuclear blue staining) was used as a counterstaining. 
Figure 21. Efficiency of transfection of APP-GFP cDNA upon 24 h of CHO transfection; a) WB of APP 
expression in APP-GFP transfected CHO cells using the anti-APP 22C11 antibody. Exogenous APP-GFP 
correspond to the upper two bands nearer 150 kDa; b) Percentage of CHO cells transfected with APP-GFP. 
The number of transfected cells (green channel) and total cells (phase contrast brightfield) were scored in 
various microscope fields, and the percentage of transfected cell calculated, for each amount of cDNA 
transfected. 
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The efficiency of transfection was higher when 1.5 µg of APP-GFP was used, but again cells 
presented apoptotic nucleus (data not shown). Hence, for further experiments we decided to use 
1.0 µg of APP-GFP. 
 
Three different antibodies against CD81 were acquired: two mouse monoclonal antibodies 
(clone M38 and 1D6; Abcam) and one rabbit monoclonal antibody (EPR4244, Abcam). MAb 
(monoclonal antibody) M38 was the first antibody acquired. It was tested in WB assays but never 
gave a signal at the various dilutions tested (from a 1:2000 dilution that was concentrated in up 
1:500). The substitute mAb 1D6 (sent by the company) did not work either in WB, although 
according to the antibodies datasheets, should work in WB. The third one send by the company, 
the rabbit monoclonal antibody EPR4244 only works in WB. We tested this mAb in three different 
dilutions: 1:2000 (recommended), 1:1000 and 1:500. This mAb did not work well at any dilution, so 
we also concentrated the secondary antibody (to 1:2500, instead of 1:5000). The dilution that 
worked better was 1:1000, with a secondary goat anti-rabbit dilution at 1:2500. Although the 
antibody worked, the signal obtained was not very good, and hence we have also acquired an anti-
RFP antibody against mApple-tag (used at recommended 1:500 dilution). The mAb M38 and 1D6 
antibodies where tested in ICC assays at a 1:100 dilution, and both exhibited a pattern that was 
expected for CD81 (e.g. presence at the plasma membrane and co-localization with mApple-CD81 
in transfected cells) (Figure 22).  
 
 
 
 
 
 
 
Figure 22. Immunocytochemistry of SH-SY5Y cells transfected with mApple-CD81. The anti-CD81 M38 
antibody (1:100) was used, together with a secondary antibody labelled with Alexa Fluor 488 (green). As 
expected, the M38 antibody perfectly co-localized with mApple-CD81, showing sensitivity and specificity 
against the CD81 protein.  
Merge mApple-CD81 CD81 M38 
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M38 and 1D6 probably only recognize the native form of CD81, so they were only used in 
ICC and IP assays, while the anti-CD81 EPR4244 and anti-RFP were used in WB assays. The full detail 
list of anti-CD81 antibodies, the applications that they should work for, and the tested applications 
are present in Table 9.  
Table 9. Purchased antibodies against CD81: species reactivity, expected applications and confirmed 
applications and dilution upon optimization.  
 
 
  
Antibodies 
against CD81 
Species 
reactivity 
Expected applications 
Confirmed 
applications 
Dilution 
M38 
Rabbit, Cat, 
Human 
WB, IP, IHC-F, Functional 
Studies, ICC, FC 
ICC 1:100 
1D6 
Human, 
Chimpanzee 
WB, IP, IHC-F, Functional 
Studies, ICC, FC 
ICC, IP 
ICC:1:100 
IP: 5µg 
ERP4244 
Mouse, Rat, 
Human 
WB WB 1:2000 
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4.3 Study of CD81 expression and subcellular localization in different cells 
As previously reported, CD81 is expressed on most human tissues and its subcellular 
localization is well known in immune system cells and in mouse oocytes33. CD81 was also recently 
showed to be present in mouse sperm cells99. 
In the present work, the expression of CD81 was evaluated in cell lines of different species 
and in human sperm cells. Since CD81 is expressed in the surface of oocytes, we decided to study 
its expression in a Chinese hamster ovary (CHO) cell line. We also used the mouse CG-1 spg cell line 
to investigate the expression of this protein in a male germ cell line. To further assess the expression 
of CD81 in a neuronal cell line, the SH-SY5Y cell line was also used. Cells were plated on a 100 mm 
culture plates, collected and subjected to a WB; the expression of CD81 was also analysed in human 
sperm cells lysates (Figure 23).  
 
 
 
 
 
 
 
Figure 23 shows that CD81 is expressed in all the cell lines tested (CHO, GC-1 and SH-SY5Y) 
and also in human capacitated sperm cells. A major band could be observed as the expected 
molecular weight of CD81, approximately 24 kDa, as described for cell lines of the immune system. 
A second fainter band could also be observed above, and may correspond to a post-translational 
modified CD81.  
Since CD81 is expressed in the cells lines tested, it was important to investigate its 
subcellular localization. Unfortunately, our anti-CD81 antibodies that work in ICC do not react with 
hamster or mouse species. Taking this limitation into account, the subcellular localization of 
endogenous CD81 was only performed in SH-SY5Y cells. CD81 was stained with the monoclonal 
anti-CD81 M38 antibody, labelled with a secondary and Alexa Fluor 594-linked antibody (red 
fluorescence), and monitored with a confocal microscope (Figure 24). 
 
Figure 23. CD81 expression in CHO, GC-1 and SH-SY5Y cells, and in capacitated sperm cells. Immunoblot of 
cells lysates probed by anti-CD81 EPR4244 antibody.  
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Figure 24. Subcellular localization of CD81 in SH-SY5Y cells. ICC was performed with anti-CD81 M38 
monoclonal antibody, labelled with a secondary anti-mouse Alexa Fluor 594-linked antibody.   
 
By analysing the Figure 24, it is possible to observe that CD81 is highly concentrated at the 
cell plasma membrane, as expected.  
Given that we successfully detected the presence of CD81 in human sperm, we further 
analysed the subcellular localization of this protein in sperm cells, and investigated if its distribution 
pattern changed during capacitation. For this purpose, sperm cells were allowed to capacitate, and 
an ICC was performed using anti-CD81 M38 antibody (green fluorescence) and an anti-
phosphotyrosine antibody (red fluorescence). This latter was used to confirm the capacitated status 
of sperm cells (Figure 25).  
As seen in Figure 25, CD81 immunoreactivity was predominantly detected in the sperm 
head and in the midpiece, but could also be observed in the entire length of the tail. ICC 
experiments using the anti-CD81 M38 antibody showed a fainter uniform fluorescence over the 
entire surface, and several small strongly fluorescent spots along the entire sperm surface. The 
head CD81 staining pattern did not change in capacitated vs non-capacitated (arrow in Figure 25) 
sperm cells, but CD81 appears to be more intense in the tails of non-capacitated sperm cells. Of 
note, the CD81 staining was specific, since no fluorescence was observed in the negative controls 
(absence of primary antibody; data not shown). 
Since CD81 is located in the sperm head, we further confirmed if this protein has an 
acrosomal localization. For this purpose, human capacitated sperm cells were stained with the anti-
CD81 M38 antibody (Alexa Fluor 594, red) and with PSA-FITC (green), an acrosome marker (Figure 
26).   
 
CD81 M38 DAPI Merge 
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Figure 25. Subcellular localization of CD81 in human non-capacitated and capacitated sperm cells. Sperm cells 
were stained with anti-CD81 M38 antibody (green) and anti-phosphotyrosine (red) after induced 
capacitation. Arrow indicates non-capacitated sperm cell. Front view.  
   
   
 
 
 
 
 
 
 By analysing Figure 26, it is possible to verify that some of the CD81 cellular pool co-localizes 
with PSA-FITC, indicating that CD81 is also located in the acrosome membrane. These sperm cells 
labelled PSA-FITC have an intact acrosome, since they did not undergo acrosome reaction. The side 
view represented in this figure allow us to better understand that CD81 is localized in the midpiece 
and in the sperm head, more specifically concentrated in the acrosome membrane.   
CD81 M38 
CD81 PSA-FITC Merge 
Figure 26. Subcellular localization of CD81 in acrosome-intact sperm cell. Capacitated sperm cells were 
stained with the anti-CD81 M38 antibody (red) and FITC - labbeled Pisum sativum agglutinin (PSA-FITC) 
(green).  
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4.4 Unravel the association between CD81 and APP 
As previously described, CD81 was identified by us as an APP putative interaction partner in a 
YTH screen using APP as a bait and a testis cDNA library. Once a protein-protein interaction is 
identified, it is necessary to validate the interaction and establish the physiological function of the 
given interaction in a biological system. A combination of methods can be used to confirm the 
physical interaction and unveil the physiological significance of an interaction100.  
 
Co-immunoprecipitation is an in vitro protein-protein interaction detection method that 
allows to confirm interactions using whole cell extracts. Since CD81 is expressed on the oocytes 
surface, and due to its role in sperm-oocyte interaction, CHO cells were first used to study the 
physical interaction between CD81 and APP. However, tetraspanins are present in a detergent-
resistant membrane environment called TEM, and so the choice of the lysis detergent to be used, 
in which these interactions can be retained, is a critical step of cell lysis. Taking this into account, 
different detergents were used along the co-immunoprecipitation procedures.  
In the first experimental design, non-transfected and mApple-CD81 transfected CHO cells 
were used. After 24h of transfection in 100 mm cell culture plates, cells were harvested, lysated 
with 1% NP-40, and a CD81 co-immunoprecipitation was performed (Figure 27).  
 
 
 
 
 
 
 
 
 
Figure 27. Co-immunoprecipitation of CD81 proteins in CHO cells, upon using 1% NP-40 as the lysis detergent. 
Co-immunoprecipitation of CD81 was performed using the anti-CD81 1D6 antibody, and CD81 
immunoblotted with the anti-RFP antibody to ensure that mApple CD81 was successfully 
immunoprecipitated. The anti-APP 22C11 antibody was used to test if APP co-precipitated with CD81. IgG, 
Immunoglobulins used as immunoprecipitation control; NT, Non transfected. 
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Figure 27 shows that mApple-CD81 could be detected in cell lysates of cells transfected with 
mApple-CD81, and that it was efficiently immunoprecipitated by the 1D6 antibody. Unfortunately, 
APP was not co-immunoprecipitated with mApple-CD81 in these experimental conditions, although 
it could be readily detected with the 22C11 antibody. 
To further clarify if CD81 and APP physically interact, we have decided to perform RFP- and 
GFP-Trap® Pull down assays. This fast and efficient method enables the purification of GFP- and 
RFP-fusion proteins, and of their binding partners, with the advantage that the bound fraction does 
not contain any immunoglobulin chain. In this procedure, we have chosen a different detergent as 
lysis buffer, and used 1% Triton-X to test if the CD81-APP complex could be retained in this new 
condition. RFP- and GFP-Trap pull down assays were carried out using cellular extracts (lysed with 
1% Triton-X) of CHO cells under different co-transfections conditions. In order to 
immunoprecipitate mApple-CD81, RFP-Trap was performed in CHO cells expressing both mApple-
CD81 and APP-GFP; as controls we have used cell co-transfected with the mApple empty vector and 
either the pEGFP-N1 empty vector, or APP-GFP. For the APP-GFP pull-down, a GFP-Trap was 
performed in CHO cells expressing both mApple-CD81 and APP-GFP; controls used were cells co-
transfected with pEGFP-N1 and mApple-CD81. Cells were plated in 32 mm plates, harvested 24 h 
after transfection, and subject to the pull-down assay. The immunoblot was probed with anti-APP 
22C11 and anti-RFP antibodies (Figure 28).  
 
 
Figure 28. Immunoblot analysis of CHO cells subject to RFP- and GFP-Trap® pull down assays. CHO cells 
grown in 32 mm cell culture plates and were co-transfected with: mApple:GFP vectors; mApple vector:APP-
GFP; GFP vector:mApple-CD81 and APP-GFP:mApple-CD81. Cell lysis was performed with 1% Triton-X, and 
mApple- and GFP-fused proteins precipitated with RFP- and GFP-Trap beads, respectively (right blot). 
Immunoblot analysis was performed with the anti-APP 22C11 and anti-RFP antibodies to detect APP and 
mApple-CD81. Arrow indicates mApple-CD81. A strong band of a lower molecular weight, corresponding to 
mApple vector alone, can be observed in mApple vector expressing cells. 
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The results first show that CHO cells were successfully co-transfected with APP-GFP and 
mApple-CD81. The immunoblotting with anti-APP 22C11 antibody detected endogenous APP and 
APP-GFP in cell lysates, and in some conditions of the pull-down assays.  Regarding the GFP-Trap, 
APP-GFP was successfully pulled-down as we can see by the presence of this protein in the 
precipitates of cells co-transfected with APP-GFP and mApple-CD81. Unfortunately, we can not 
infer if mApple-CD81 was immunoprecipitated with APP-GFP as the anti-RFP antibody had a bad 
signal-to-noise ratio that difficult bands perception in the GFP-Trap precipitates. Also due to this, 
we also can not ensure that the RFP-Trap pulled down the mApple-CD81 proteins, since we could 
only detect mApple-CD81 in the cell lysates. Further, since APP-GFP was pulled-down by mApple-
CD81 but also by the mApple tag alone (please see RFP-Trap lanes), this make it impossible to draw 
definitive conclusions on a potential APP-CD81 interaction. 
Various problems could have occurred. Since CHO cells were somewhat resistant to the 
lysis buffer used (Triton-X) and the RFP- and GFP-Trap procedure were performed in 32 mm plates, 
the total amount of protein used in these pull-down assays could be not enough to detect CD81 in 
the pulled-down samples. The fact that both proteins were tagged may have interfered with their 
interaction. In an attempt to overcome this, another CD81 and APP co-immunoprecipitation was 
performed in SH-SY5Y cells transfected with untagged APP and CD81 cDNAs. Cell lysis was 
performed with the mild detergent CHAPS. Unfortunately, it was again not clear if CD81 was 
successfully immunoprecipitated and co-immunoprecipitated, since the intense signal from the 
immunoglobulin light chains overlapped the CD81 band signal.  
  
 
In the co-immunoprecipitation procedures, different cell lines and lysis buffers were used. 
Although we were not able to confirm the physical interaction between CD81 and APP, an apparent 
functional interaction between these two proteins appeared from our experiments. To further 
evaluate if CD81 overexpression had an effect in endogenous APP levels, SH-SY5Y and CHO cells 
were transient transfected with increasing amounts of CD81 (0.5, 1.0, 1.5 and 2.0 µg of pCDM8 
hCD81 cDNA; this last amount was only performed in CHO cells). APP levels was detected by 
immunoblot procedures, its levels quantified and expressed as fold-increase over basal levels in 
pCDM8 transfected SH-SY5Y cells, or in non-transfected CHO cells. The analysis of total sAPP in SH-
SY5Y cells medium was also performed. Ponceau S staining of total proteins bands was performed 
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for all assays, and used as a loading control in the quantification analysis. Results are presented in 
Figure 29. 
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pCDM8 hCD81  
150 kDa 
100 kDa 
NT  
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Figure 29. Evaluation of the influence of CD81 
overexpression in APP levels, upon 24h of cells 
transfection with increasing amounts of pCDM8 
hCD81. Detection of endogenous cellular APP and 
extracellular sAPP were performed using the anti-
22C11 antibody. a) WB and quantitative analysis 
of APP levels in SH-SY5Y cells overexpressed with 
CD81 cDNA (0.5, 1.0 and 1.5 µg) Data are 
expressed as endogenous APP fold increase over 
vector (pCDM8) expressing cells. b) WB and 
quantitative analysis of sAPP media levels 
secreted by SH-SY5Y cells transfected with 
increasing amounts of CD81 cDNA (0.5, 1.0 and 1.5 
µg). Data are expressed as sAPP fold increases 
over vector (pCDM8) expressing cells. c) WB and 
quantitative analysis of APP levels in CHO cells 
overexpressed with CD81 cDNA. Data are 
expressed as endogenous APP fold increases over 
non-transfected cells. a) and b) Data are 
presented as mean±SEM, upon correction to 
Ponceau. n=3. c) Data are presented as mean, 
upon correction to Ponceau. n=2. 
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Regarding the influence of CD81 overexpression in the APP levels of SH-SY5Y cells (Figure 
29a), we can observe that the cellular transfection with 0.5 and 1.0 µg of pCDM8 hCD81 induced a 
slight increase in the levels of APP. This tendency was abolished when cells were transfected with 
1.5 µg of pCDM8 hCD81, and APP levels were again similar to vector transfected samples. This 
decrease could be due to the cellular toxicity of the higher CD81 overexpression condition. Since 
CD81 transfection led to a slight increase in APP levels, it was relevant to investigate if this increase 
could be due to a decrease in APP cleavage into sAPP. Cell media were collected for each condition 
and analysed by WB using the anti-22C11 antibody (Figure 29b). After total sAPP quantification, 
evidences showed that CD81 overexpression did not affect sAPP production.  
CHO cells seem to respond slight differently to CD81 overexpression than SH-SY5Y cells, 
probably due to its different tissue nature. To understand the effect of CD81 overexpression in CHO 
cells, a similar approach was used and APP levels were evaluated in CHO cells transfected with 0.5, 
1.0, 1.5 and 2.0 µg of pCDM8 hCD81 (Figure 30c).The results obtained with CHO cells also indicate 
that CD81 overexpression increases APP levels. However, it seems that this CD81 effects is more 
prominent in CHO cells than in SH-SY5Y cells. Since the sAPP levels in CHO cells medium were not 
evaluated, we can not infer about the mechanism(s) underlying the increase in APP levels. The 
hypotheses that CD81 promotes APP´s half-life or induces APP gene expression will also be further 
addressed in the future. 
 
 
Co-localization experiments in cultured cells can give information about the spatial 
dynamics of protein-protein interactions. Although we were not able to prove the physical 
interaction between APP and CD81, we further analysed potential subcellular regions of CD81 and 
APP in vivo co-localization trough immunocytochemistry. This procedure was carried out in sperm 
cells, and in SH-SY5Y cells non-transfected and co-transfected with mApple-CD81 and APP-GFP 
cDNAs. APP was stained with the anti-APP CT695 (labelled with red Alexa Fluor 594 in sperm cells, 
and with green Alexa Fluor 488 in SH-SY5Y cells), and endogenous CD81 was stained with anti-CD81 
M38 (green Alexa Fluor 488 in sperm cells, and red Alexa Fluor 594, red in SH-SY5Y cells). 
Fluorescence microphotographs were taken at the cellular membrane plane by using a confocal 
microscope (Figure 30 and 31). All images retrieved from the endogenous CD81 and APP co-
localization assays in SH-SY5Y cells were analysed using the Fiji software. 
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By analysing the Figure 30 it is possible to observe that the anti-APP CT695 antibody 
immunoreacts with the entire sperm cell, although it is highly concentrated in the midpiece, where 
the signal was more intense. It is also possible to observe that the sperm head is positively stained. 
Confocal fluorescence microscopy showed that the anti-APP CT695 staining presented some degree 
of co-localization with the CD81 staining. As showed in the magnified ROI (region of interest of 
Figure 30), this co-localization seems to be in the midpiece region and in some fluorescent spots in 
the sperm head, at least in the post-acrosome region. No real co-localization was observed along 
the tail.  
The co-localization of CD81 and APP in SH-SY5Y cells was also analyzed using again the anti-
APP CT695 to detect APP (green) and anti-CD81 M38 to detect CD81 (red) (Figure 31). 
 
 
 
 
Figure 30. APP and CD81 subcellular co-localization in human capacitated sperm cells. APP protein was stained 
with anti-APP CT695 antibody (Alexa Fluor 594, red) and CD81 protein was stained with anti-CD81 M38 
antibody (Alexa Fluor 488, green). ROI, region of interest.  
APP CT CD81 Merge 
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Figure 31. CD81 and APP subcellular co-localization in SH-SY5Y cells. a) and b) Endogenous CD81 and 
endogenous APP subcellular co-localization in non-transfected SH-SY5Y cells. APP proteins were labelled with 
the anti-APP CT695 antibody (Alexa Fluor 488; green fluorescence) and CD81 proteins were labelled with the 
anti-CD81 M38 antibody (Alexa-Fluor 594; red fluorescence). c) CD81 and APP subcellular co-localization in 
SH-SY5Y cells upon 24 h of co-transfection with APP-GFP and mApple-CD81 cDNAs.  
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Regarding the distribution of each of the proteins alone, APP CT695 antibody revealed that 
APP is mainly present in the Golgi apparatus and nearby regions, with a small fraction of APP being 
present in the plasma membrane. Regarding CD81 it is mainly localized at the plasma membrane, 
being more especially abundant in membrane extensions such as filopodia. 
Regarding APP/CD81 co-localization, confocal fluorescence microphotographs showed that 
endogenous CD81 and APP present some degree of co-localization, particularly at the plasma 
membrane, including cellular processes (Figure 31a). 20 microphotographs were analysed with the 
ImageJ Fiji software, and approximately 33% of the CD81 cellular pool was found to co-localize with 
APP. Figure 31b and its ROI show that CD81 is enriched in the cellular membrane, mainly in cell-to-
cell and cell-to-subtract communication filopodia (‘finger’-like extruding structures). CD81 and APP 
co-localized in these filopodia and in some plasma membrane regions. A small pool of endogenous 
CD81 and APP were also observed to co-localize throughout the entire cytoplasm.  
When SH-SY5Y cells were co-transfected with APP-GFP (green) and mApple-CD81 (red), 
cells attained a motile phenotype and a high degree of APP/CD81 co-localization was observed. This 
co-localization mainly occurs at the plasma membrane and in various large cytoplasmic spots. Of 
note, various APP-GFP-positive small vesicles do not co-localize with mApple-CD81. The nature of 
the subcellular regions of co-localization in the cytoplasm will have to be further analysed by using 
specific organelle markers.  
 Combining the overall data, we were not able to confirm that CD81 and APP physically 
interact but data from CD81 overexpression experiments suggest that CD81 has an effect on APP 
levels and CD81 and APP subcellular co-localization analyses show that probably these two proteins 
physically interact in vivo and are involved in a common biological process.  
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4.5 CD81 and other interacting proteins  
Since CD81 seems to be involved in signalling pathways related with cytoskeleton 
remodelling and cell motility, an evaluation of its co-localization with AKT, and the influence of its 
overexpression in cytoskeleton proteins levels, namely in actin and tubulin, was performed. 
 
 
As depicted in section 4.1, AKT (also known as Protein Kinase B) is a CD81 interacting 
protein. When activated, AKT phosphorylates a number of substrates involved in cytoskeleton 
remodelling, cell growth and cell survival in neurons, and also in sperm cells. To better understand 
the CD81 and AKT subcellular distribution, a co-localization assay was performed in sperm cells and 
in SH-SY5Y cells (Figures 32 and 33, respectively). This experiment was performed using an anti-
AKT1 antibody to detect AKT isoform 1, and anti-CD81 M38.  
 
 
 
 
 
 
  
Figure 32 shows that AKT1 is present in human capacitated sperm cells, as expected, and 
although weaker, the immunostaining with the anti-AKT1 antibody indicated that AKT1 is mainly 
expressed in the sperm head, although a small protein pool is also present along the entire tail. 
Regarding its co-localization with CD81, few co-localization was observed. This could be due to the 
weak AKT immunostaining and so more experiments have to be done to better understand their 
subcellular co-localization in sperm cells.  
 
 
AKT1 
CD81 Merge AKT1 
Figure 32. CD81 and AKT1 subcellular co-localization in human capacitated sperm cells. AKT1 protein was 
stained with the anti-AKT1 antibody (labelled with Alexa Fluor 594, red) and the CD81 protein was stained 
with the anti-CD81 M38 antibody (labelled with Alexa Fluor 488, green).  
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 Regarding AKT1 distribution in SH-SY5Y cells (Figure 33), microphotographs showed that 
AKT1 is localized throughout  the cytoplasm, which is in agreement with previous reports101. 
Although CD81 is mainly localized at the plasma membrane, Figure 33 shows also some cytoplasm 
localization and some degree of CD81 co-localization with AKT1. Surprisingly, this co-localization is 
predominantly at the inner leaflet of the plasma membrane and at the cell projections (Figure 33, 
ROI). Few localization between these proteins was observe in the cytoplasm. Overall, our data 
demonstrated that in SH-SY5Y cells these proteins co-localized in specific cellular compartments, 
supporting their physical interaction in vivo. 
 
 
Figure 33. CD81 and AKT1 subcellular co-localization in non-transfected SH-SY5Y cells. AKT1 protein was 
stained with the anti-AKT1 antibody (labelled with Alexa Fluor 488, green) and CD81 was stained with anti-
CD81 M38 antibody (labelled with Alexa-Fluor 594, red). ROI, region of interest 
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In order to better understand the influence of CD81 in cytoskeleton remodelling, we aimed 
to perform a co-localization procedure with CD81-binding cytoskeleton-related proteins. 
Unfortunately, our anti-actin and anti-tubulin antibodies are both raised in mouse, what did not 
allow to perform the co-localization between these proteins and CD81. To overcome this problem 
of lack of an anti-actin antibody, Alexa Fluor 568 Phalloidin, a drug that binds to F-actin and is red 
fluorescing, was used to stain the polymerized filamentous actin (F-actin), and determine its co-
localization with CD81 (stained with anti-CD81 M38,in green). The results for sperm cells are 
presented in Figure 34.  
 
 
 
 
 
 
 
A weak F-actin staining can be observed in the sperm head, and no or few staining in the 
tail. Regarding the sperm head, is seems that F-actin is enriched in the post-acrosomal region, and 
this would be the zone where it could co-localize with CD81, but F-actin staining was too weak to 
draw definitive conclusions. Further, since during capacitation and acrosome reaction, the 
relocation of the cytoskeleton proteins is likely to be important for subsequent events of 
fertilization, more experiments have to be done to access the subcellular localization between CD81 
and cytoskeleton-related proteins.   
In our previous experiments we observed that CD81 overexpression seemed to induce 
morphological changes in SH-SY5Y cells. This most probably comprised alterations in the levels or 
polymerization state of cytoskeleton proteins, namely actin and tubulin. The effects of 
overexpressing increasing amounts of CD81 in SH-SY5Y cells in β-actin and Acetylated α-tubulin 
Figure 34. CD81 and filamentous actin (F-actin) o-localization in human capacitated sperm cells. CD81 protein 
was stained with the anti-CD81 M38 antibody (labelled with Alexa Fluor 488, green), and F-actin with Alexa 
Fluor 568 phalloidin (red). DAPI (blue nuclear staining) was used as a counterstaining. 
F-actin CD81 Merge 
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levels were evaluated by immunoblot analysis. Ponceau staining of total proteins in the membrane 
is shown as a loading control (Figure 35).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results indicate that β-actin levels seem to decrease when cells were transfected with 1.0 
and 1.5 µg of pCDM8 hCD81, when compared to empty vector-transfected cells (Figure 35a). 
Acetylated α-tubulin is a post-translational modification that is found microtubules that are 
relatively stable. Figure 35b shows that the levels of acetylated tubulin are also affected by CD81 
transfection. In this case however, acetylated tubulin seems to mainly increase with the 
transfection of increasing amounts of CD81. More experiments will be performed to confirm and 
quantify these effects.  
In a second approach, an ICC was performed in SH-SY5Y cells transfected with 1.0 µg of 
pCDM8 hCD81 for 24 h, in order to access the subcellular co-localization between F-actin (marked 
with Alexa Fluor 568 Phalloidin) and the CD81 protein (Figure 36). Results show that SH-SY5Y cells 
that were transfected with 1.0 µg of pCDM8 hCD81 acquired a migratory phenotype, as we can see 
by their more ‘triangular’ shape. Indeed, transfected cells presented a polarized and asymmetric 
morphology, and active membrane processes, including F-actin containing filopodia at the cell 
leading edge. Regarding transfected CD81, we can observe that this protein is enriched in the 
plasma membrane and along the cytoplasm. Of note, when z-stacks of cells were taken using 
confocal fluorescence microscopy, big spots with CD81 accumulation were visible in the cytoplasm, 
and some of them crossed the entire cytoplasm (data not shown). The microphotographs further 
showed a high degree of co-localization between transfected CD81 and F-actin. This co-localization 
was mainly visible along the F-actin stress fibres that crossed the cell, in potential focal adhesion 
Figure 35. Western blot analyse of β-actin (a) and Acetyl α-tubulin (b) expression with conditions of CD81 
overexpression in SH-SY5Y transfected cells. SH-SY5Y cells were transfected with 0.5, 1.0 and 1.5 µg of pCDM8 
hCD81 for 24 h.  
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spots, and also in the filopodia. These results suggest a role for CD81 in promoting cellular 
mechanisms that underlie the acquisition of a clear migratory phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells with a migratory phenotype.  
  
  
F-actin F-actin 
CD81 
Merge 
CD81 
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Figure 36. CD81 and F-actin subcellular co-localization in SH-SY5Y cells transfected with 1.0 µg of pCDM8 
hCD81. CD81 protein was stained with anti-CD81 M38 antibody (green) and F-actin was probed with 
Alexa Fluor 568 Phalloidin (red). ROI, region of interest. 
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 Discussion and conclusion 
 
CD81 is a tetraspanin protein that has been mainly studied in the immune system. Few 
functions have been attributed to it, but it is known to be involved in processes such as cell adhesion 
and migration. Its expression levels, subcellular distribution and role in other cells, such as neuronal 
and germinal cells, are still barely known. A powerful approach for inquiring the biological functions 
of a protein of interest is to analyse its protein-protein interactions (PPIs). In the present work we 
aimed to characterize CD81 and some of its protein interactors in various cell lines and in human 
sperm cells. We mainly focused in its binding to APP, since an APP-CD81 interaction was originally 
identified in our lab in a YTH screen of human testis cDNA library when APP was used as a bait46.  
 
CD81 expression and subcellular distribution 
Before studying the CD81 interactors, we have characterized CD81 expression and 
subcellular localization in different cells lines and in human sperm cells. CD81, as expected due its 
known large tissue distribution, was expressed in CHO, GC-1 and SH-SY5Y cell lines. In all cell lines 
tested (and in sperm cells), the molecular weight of the more intense CD81 band was ~24 kDa, as 
expected; a second fainter upper band appeared in all cell lines tested, and a fainter lower band 
appeared in GC-1 cell line, probably due a CD81 cleavage. CD81 does not suffer glycosylation, but 
undergoes palmitoylation and phosphorylation. This shift could hence correspond to two added 
phosphate groups, but this need to be further investigated.  
Regarding CD81 subcellular distribution in SH-SY5Y cells, it is mainly expressed at the 
plasma membrane, but it can also be found in some accumulations in the cytoplasm. The small 
cytoplasmic spots could be exosomes, since CD81 is enriched in exosomes-like vesicles36. CD81 
expression in this nervous system-related cell line is not surprising. Although the major role of CD81 
is described in the immune system, CD81 has been implicated in the nervous system. Dijkstra et al. 
(2000) show that CD81 is dramatically up-regulated after spinal cord injury. CD81 is found 
concentrated at regions of cell-cell contact in cultured astrocytes and may play a central role in the 
process of CNS scar formation that involves various cellular populations: microglia, invading 
monocytes, and reactive astrocytes102.  CD81 is required for the normal development of the brain. 
Geisert et al. (2002) performed a study in order to examine the effects of the CD81 -/- mutation on 
the CNS of mice and showed that these mice have extremely large brains. This was as a result of an 
increased number of astrocytes and microglia, whereas the number of neurons and 
oligodendrocytes appeared to be normal103. Hence, CD81 controls astrocytes and microglia cell 
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number, now known to occur by suppressing cell proliferation in a cell-cell contact-dependent 
manner104.  
Regarding the expression of CD81 in germinal cells, it has been reported that CD81 is 
located on the surface of oocytes and in cumulus cells43. Ohnami et al. (2012)44 showed that CD81 
is localized at the inner portion of ZP and hypothesized that it may be involved in any step of the 
fusion-related events that occur prior to sperm-oocyte membranes fusion. These authors also 
showed that CD81 is expressed in mouse sperm cells and, taking this into account, we further 
investigated if it was also expressed in human sperm cells. The present study provides the first 
evidence of the presence of CD81 in human sperm cells (Figure 25). The same pattern of CD81 
expression was visible, with two CD81 bands appearing at the expected MW. Subsequent ICC 
evaluations revealed that CD81 immunoreactivity was predominantly detected in the sperm head 
including the acrosome membrane, and in the midpiece, being also present at lower abundance 
along the entire tail (Figure 26). The pattern of immunostaining seems to be altered during sperm 
capacitation, with CD81 being apparently less present in the sperm tail, but this needs to be further 
confirmed. Further, its localization after the acrosome reaction was not evaluated yet. These results 
lead us to speculate on the following points: 1) CD81 in the head and midpiece membranes may 
serve as an organizer for other proteins, forming tetraspanin webs necessary for signalling events 
related to acrosomal reaction and sperm motility; and 2) CD81 may play a role in the sperm-oocyte 
fusion event. This last hypothesis is of particular interest if we consider that egg proteins released 
from the oocyte surface could attach to the sperm surface. Indeed, before sperm-oocyte fusion, 
CD9 (a tetraspanin partner of CD81 located in oocyte surface) is transferred to the sperm 
membrane44. The authors hypothesized that CD81 is to be transferred first from the oocyte to the 
sperm membrane to support the subsequent transfer of CD9 through the formation of a complex 
between these two proteins. Hence, since CD81 can form dimers and bind CD9, sperm CD81 may 
bind to oocyte-transferred CD81 and CD9, forming a tetraspanin-tetraspanin binding complex 
between the sperm and oocyte surface, to facilitate the subsequent membranes fusion. More 
studies need thus to be performed to confirm the exact surface location of this protein in human 
sperm, and to prove this hypothesis.  
 
CD81 and cytoskeleton remodelling 
To better understand the CD81 physiological role, we first performed a bioinformatics 
analysis of its interacting proteins. A CD81 PPI network was constructed, and GO terms enrichments 
of these interactors were performed. A majority of CD81 interacting proteins are located in the 
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cytoplasm and nucleus, and are involved in the determination of DNA and RNA fates, or in cell 
metabolism, as revealed by GO enrichments in biological processes and functions. The 
bioinformatics pathways analysis showed that CD81 is linked to intracellular signalling components 
involved in cytoskeletal regulation by Rho GTPase family members, in the integrins signalling 
pathway and, surprisingly, in pathways related to the proteolytic cleavage of APP. From the proteins 
that were classified as involved in the CD81 signalling pathways, AKT1, RAC and cytoskeleton-
related proteins as tubulin and actin are key players in CD81 signalling pathways.  
AKT1, an AKT isoform, is a kinase involved in a variety of signalling pathways related to 
motility, cell survival and cytoskeleton remodelling in cells. In the present work, we performed an 
ICC in sperm cells and in SH-SY5Y cells to access the subcellular localization of CD81 and AKT1. A 
weak but visible immunostaining was obtained when using the anti-AKT1 antibody in sperm cells. 
Regarding its subcellular localization, our results are particularly distinct from the published data, 
since we observed an immunostaining in the head and Sagare-Patil et al. (2013) described that total 
AKT is only present in the midpiece and tail105. When AKT is activated by phosphorylation in the 
cytoplasm, it is targeted to the inner leaflet of the plasma membrane and phosphorylates a number 
of subtracts106. In sperm cells, AKT pathway can be activated by progesterone and is required for 
motility and sperm cell survival. Unfortunately, our co-localization results did not allow to take any 
conclusion. An optimization of the ICC in human sperm with this antibody needs to be done to 
better understand the subcellular AKT1 localization and AKT1/CD81 co-localization. However, in SH-
SY5Y cells, AKT1 presented the expected subcellular localization along the entire cytoplasm. 
Interestingly, the co-localization of CD81 and AKT1 seems to be prominent at the inner leaflet of 
the plasma membrane. This result indicates that CD81 co-localizes with the active AKT1, and may 
indicate that CD81 participates in the PI3K/AKT pathway. Interestingly, Milosch, et al. (2014)107 
shows that in neuronal cells APP serves as a receptor for the sAPPα, to trigger G-protein-dependent 
activation of PI3K. This activation leads to the recruitment and downstream activation of the pro-
survival kinase AKT, mediating sAPPα-induced neuroprotection. Our findings suggest that in SH-
SY5Y cells, the CD81-AKT complex may be involved in cell survival and proliferation. Co-localization 
studies using antibody for the phosphorylated AKT should thus be performed to unveil the role of 
this complex in neural cells.  
Rac is a member of the Rho-family of proteins (as Rho and cdc42), molecules that bind actin 
and regulate the actin cytoskeleton remodelling108. CD81 seems to be intimately involved in 
cytoskeleton remodelling, as Brazzoli et al. (2008)109 showed that it increases the levels of activated 
Rac1, RhoA and Cdc42 in Huh-7 cells. Hence, CD81 engagement (via antibody binding) induces Rho 
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family GTPase-dependent actin rearrangements that are involved in e.g. hepatitis C virus (HCV) 
infection. Actin remodelling is also involved in cell-cell adhesion, cell ECM adhesion, cytoskeletal 
protrusion/contraction, proteolytic ECM remodelling, and cell migration. Indeed, tetraspanins play 
important roles in the migration of many different cell types, including cancer cells, endothelial 
cells, keratinocytes, fibroblasts, and leukocytes110. A direct association between CD81 and Rac in 
TEM seems to be involved in cell migration, as reported by Tejera et at. (2013)111. According to 
these findings, CD81 regulates Rac1 dynamics and localization at the cell membrane during 
membrane protrusion, and formation of adhesion complexes and establishes a mechanism through 
which CD81 regulates cell migration. CD81-Rac complexes were most prominent at the cell leading 
edge, in which Rac promotes actin polymerization into F-actin and the formation of dendritic actin 
branches, favouring the initial steps in adhesion formation. Moreover, actin itself is a CD81 
interacting protein, as described by Perez-Hernandez et al. (2013)112 (Appendix 1-Table 1 and Figure 
14). In agreement with these findings, we observed that CD81 staining perfectly matches with F-
actin staining in stress fibres and filopodia of the leading edge of migrating SH-SY5Y cells (Figure 
36). Further, we have also observed that CD81 is highly abundant in cellular spots that transverse 
the cell cytoplasm and appear to be focal adhesions (data not shown). These observations reinforce 
a role of CD81 in cell migration, and it will be very interesting to future characterize the role of CD81 
specifically in neuronal migration and in other processes that involve Rho-family-dependent actin 
rearrangements such as neuritogenesis. In fact, in SH-SY5Y cells transient transfected with 1.0 and 
1.5 µg of pCDM8 hCD81, the levels of the cytoskeleton-related proteins β-actin and Acetylated α-
Tubulin seem to be altered. While β-actin levels seem to decrease with increasing amounts of CD81, 
the levels of acetylated tubulin appear to increase (Figure 35). These kind of alterations are in 
accordance with a remodelling of the actin and microtubules cytoskeleton related with 
neuritogenic events. Indeed, we have reported that with the onset of neuritogenesis, the actin 
levels tend to first decrease, while with the elongation of cellular projections the levels of acetylated 
tubulin increase113. According to this, when we transfected SH-SY5Y cells with non-toxic amounts 
(as 1.0 g) of mApple-tagged CD81, the number of cellular projections highly increased (data not 
shown). In the future, this will be scored and related to the levels of CD81, and to the levels of beta-
actin, total tubulin, and acetylated tubulin (in triplicates).  
Regarding sperm cells, our results showed no or few immunostaining of F-actin by Alexa 
Fluor 568 Phalloidin in sperm cells (Figure 34). Cytoskeleton proteins such as actin and tubulin (α-, 
β- and γ-tubulin) are implicated in key events such as capacitation and the acrosome reaction (AR), 
and these proteins are altered after the AR. F-actin polymerization occurs during capacitation and 
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is important for the translocation of phospholipase C from the cytosol to the sperm plasma 
membrane during this proccess114. Unfortunately, we cannot infer about the distribution of F-actin 
and its co-localization between CD81 since we have only tested this in one sample, and the staining 
was very weak. This has to be further repeated, but if CD81 is involved in sperm cells motility it will 
probably be via a different mechanism than SH-SY5Y cells migration, since sperm cells migrate 
through their flagellum.  
 
CD81 and APP 
Since CD81 was one of the APP potential interactors in human testis with one of the highest 
number of positive clones, we aimed to confirm and further characterize the CD81-APP interaction. 
Our first approach was to attempt to demonstrate the formation of a complex between CD81 and 
APP in two different cell lines. CHO and SH-SY5Y cells were single transfected or co-transfected with 
CD81 and APP cDNAs and then subjected to co-IP and pull-down assays, using different lysis buffers: 
1% NP-40, 1% TRITON and 4% CHAPS. From the co-IP and pull-down assays it remained unclear 
whether CD81 and APP physically interact under the conditions tested. Three different levels of 
interactions have been proposed to occur in the tetraspanin web, based on the use of different 
detergents in the co-IP assays used to pull-down tetraspanins’ interactors40. In the present work we 
performed cell lysis with harsh detergents (1% NP-40 and 1% Triton-X-100) and a mild detergent 
(4% CHAPS). At an advance state of our study we discovered that, in and until then elusive work 
whose main aim was not APP-CD81 interaction but classified their level of interaction. Sosa et al. 
(2013)94 demonstrated by co-IP that APP forms Brij98-resistante complexes with CD81 in rat 
neuronal growth cones. We now aim to demonstrate that APP and CD81 form protein complexes 
in CHO, SH-SY5Y and human sperm cells through the use of a Brji98-containing buffer to lyse cells 
before the co-IP. We thus hypothesise that CD81 and APP physically interact by indirect 
associations, clustering with cholesterol in the TEM, as described for the Brji98-resistant tertiary 
interactions37. We hypothesize that CD81 bridges APP to these TEM membrane domains and helps 
to regulate its surface availability for cell adhesion or cleavage, and signalling via its sAPP and AICD 
fragments. Indeed, our bioinformatics analysis unravelled CD81 interacting enzymes that are 
involved in the cleavage of APP into these fragments: ADAM10 and presinilin 1 and 2 (Appendix 1-
Table 1 and Figure 14). The role of CD81 in the APP proteolytic pathway was studied in two 
independent works. By the physical interaction with the α-secretase ADAM10, CD81 was observed 
to promote the ADAM10 activity and to consequently decrease Aβ formation92. In another work, 
CD81 was seen to interact with PS1 and PS2 (proteolytic subunits of the γ-secretase complex), and 
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also to modulate their activity. This study showed that the absence of CD81 led to an accumulation 
of the AICD-precursor CTFs, indicating a partial disruption of either the γ-secretase activity or the 
interaction between γ-secretase and its CTF substrate in CD81-lacking condition52. It thus seems 
that CD81 can participate in the amyloidogenic pathway and in the non-amyloidogenic pathway. 
Contrary to the first report, our results suggests that CD81 does not significantly affect the cleavage 
of APP into sAPP, at least in SH-SY5Y cells  (Figure 29), but it probably interferes with the APP half-
life or increases the rate of APP mRNA translation. CD81 overexpression in SH-SY5Y and CHO cells 
can result in slightly higher APP levels until 1.0 µg of transfected pCDM8 hCD81 cDNA. This occurred 
in both cell lines, although the effect was more prominent in CHO cells (Figure 29). The increased 
APP translation hypothesis is supported by our bioinformatics findings that most of CD81 
interactors are involved in biological processes related to translation (Table 6). 
We next evaluated the potential cellular regions of CD81-APP interaction by monitoring 
their subcellular co-localization sites in sperm cells and SH-SY5Y cells. In our lab, we have previously 
characterized the distribution of members of the APP superfamily in sperm cells. Although their 
presence in the head (particularly at the equatorial region) suggests their possible involvement in 
sperm-oocyte interaction, no binding partner was attributed to APP/APLPs. The anti-APP C695 
antibody here used detects the C-terminal of APP and also of APLP1 and APLP2 proteins. Results 
showed that CD81 mainly co-localizes with members of the APP superfamily in the midpiece and in 
some spots of the post-acrosomal region. Our previous studies showed that the midpiece mainly 
expressed APLP2, whereas APP is present in the surface of the entire head77, suggesting that the 
co-localization in the midpiece is between APLP2 and CD81 and in the post-acrosomal region is 
between APP and CD81. Since these are specialized zones of the sperm cell, we hypothesize that 
their co-localization at the midpiece is involved in signalling pathways related to sperm motility, 
and that CD81 and APP co-localize at the sperm head for maintaining APP at the surface and 
mediate e.g. sperm-oocyte membrane-membrane adhesion. 
The ICC studies in SH-SY5Y cells showed co-localization with endogenous CD81 and APP in 
very specific subcellular sites. The co-localization was present in cellular projections in non-
differentiated cells. APP is preferentially enriched in the growing neurites and in neuritic growth 
cones, and stabilizes the neurites113. CD81 interacts with α3β1 integrin and this complex co-
distributes on neurites and growth cones of human NT2N cells. This association is functionally 
relevant, as CD81 strongly and positively contributes toward neurite number, length, and rate of 
outgrowth in this model115. Taken together with the fact that APP also binds integrins and that we 
have observed CD81 increasing the number of cellular projections, the co-localization of CD81 and 
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APP suggests that this complex may have a role in neuritogenesis and in adhesion. The ICC analysis 
showed that CD81 and APP co-localized in filopodia, which are F-actin enriched membrane 
protrusions involved in neuritogenesis, cell migration, and cell-cell communication. APP has been 
described to mediate neuronal cell-cell adhesion and CD81 is also involved in cell adhesion in the 
immune system33.  
 
In synthesis, the bioinformatics analysis and our WB/ICC results indicate that CD81 and its 
interactors such as AKT1, APP and cytoskeleton-related proteins are involved in a variety of 
signalling pathways that comprise cytoskeleton remodelling and are related to processes such as 
sperm motility and cell migration, cell survival, and neuritogenesis. Several of these data still need 
to be confirmed and further explored, but we believe that this work will help to further advance 
the knowledge on the functions of CD81 and its interactors, particularly in sperm and neuronal cells. 
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Appendix 1 
Table 1. CD81 interactors obtained from BioGrid (in black) database and PubMed publications (in grey) after manual 
curation of respective publication.  
Gene Protein 
UniProt 
ID 
Ref. 
ACTB Actin, beta P60709 112 
ACTN1 actinin, alpha 1 P12814 112 
ACTN4 Actinin, alpha 4 O43707 112 
ADAM10 
Desintegrin and metalloproteinase domain-containing protein 
10 O14672 92 
ADGRG1 Adhesion G Protein-Coupled Receptor G1 Q9Y653 116 
ADRB2 Adrenoreceptor beta 2, surface P07550 117 
AKT1 RAC-alpha serine/threonine-protein kinase P31749 112 
ALYREF Aly/REF export factor Q86V81 112 
ANP32B Acid (leucine-rich) nuclear phosphoprotein 32 family, member B Q92688 112 
APP Amyloid Beta (A4) Precursor Protein P05067 94 
ATP5A1 
ATP synthase, H+ transporting, mitochondria F1 complex, alpha 
subunit P25705 112 
ATP5O 
ATP synthase, H+ transporting, mitochondria F1 complex, O 
subunit P48047 112 
BCR Breakpoint Cluster Region P11274 118 
CCT3 Chaperonin containing TCP1, subunit 3 (gamma) P49368 112 
CCT4 Chaperonin containing TCP1, subunit 4 (delta) P50991 112 
CD14 CD14 Molecule P08571 119  
CD19 CD19 molecule P15391 120–122 
CD4 CD4 molecule P01730 121 
CD46 CD46 molecule, complement regulatory protein P15529 123 
CD53 CD53 molecule P19397 124 
CD63 CD63 molecule P08962 125 
CD74 HLA-DR Antigens-Associated Invariant Chain P04233 126  
CD81 CD81  molecule P60033 127 
CD82 CD82 molecule P27701 124 
CD9 CD1 molecule P21926 122,128 
CFL1 Cofilin 1 (non-muscle) P23528 112 
CFL2 Cofilin 2 (muscle) Q9Y281 112 
CLDN1 Claudin 1 O95832 129  
CNN2 Calponin 2 Q99439 112 
CPSF6 cleavage and polyadenylation specific factor 6, 68kDa Q16630 112 
CR2 Complement component (3d/Epstein Barr virus) receptor 2 P20023 120 
CRIP1 Cystein-rich protein 1 (intestinal) P50238 112 
CSNK2B Casein kinase 2, beta polypeptide P67870 110 
CTSC Cathepsin C P53634 130 
DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 Q92841 112 
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Gene Protein 
UniProt 
ID 
Ref. 
DDX3X DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked O00571 112 
DDX3Y DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked O00571 112 
DDX5 DEAD (Asp-Glu-Ala-Asp) box helicase 5 O00571 112 
DHX15 DEAH (asp-Glu-Ala-His) box helicase 15 O43143 112 
DLG5 Discs, large homolog 5  Q8TDM6 131 
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1  P68104 112 
EEF1A2 Eukaryotic translation elongation factor 1 alpha 2 Q05639 112 
EEF1D Eukaryotic translation elongation factor 1 delta P29692 112 
EIF3A Eukaryotic translation initiation factor 3, subunit A Q14152 112 
EIF3B Eukaryotic translation initiation factor 3, subunit B P55884 112 
EIF3C Eukaryotic translation initiation factor 3, subunit C Q99613 112 
EIF3CL Eukaryotic translation initiation factor 3, subunit C-like Q13347 112 
EIF3E Eukaryotic translation initiation factor 3, subunit E P60228 112 
EIF3F Eukaryotic translation initiation factor 3, subunit F O00303 112 
EIF3G Eukaryotic translation initiation factor 3, subunit G O75821 112 
EIF3H Eukaryotic translation initiation factor 3, subunit H O15372 112 
EIF3I Eukaryotic translation initiation factor 3, subunit I Q13347 112 
EIF3K Eukaryotic translation initiation factor 3, subunit K Q9UBQ5 112 
EIF3L Eukaryotic translation initiation factor 3, subunit L Q9Y2862 112 
EIF4A1 Eukaryotic translation initiation factor 4A1 P60842 112 
EIF4A2 Eukaryotic translation initiation factor 4A2 Q14240 112 
EWSR1 EWS RNA-binding protein 1 Q01844 112 
EZR Ezrin P15311 132  
FAM98B Family with sequence similarity 98, member B Q52LJ0 112 
FAU 
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) 
ubiquitously expressed P62861 112 
FLNA filamin A, alpha P21333 112 
FUBP1 Far upstream element (FUSE) binding protein 1 Q96AE4 112 
GAPDH Glyceraldehyde-3-phophate dehydrogenase P04406 112 
GGT1 Gamma-glutamyltransferase 1 P19440 124 
GLP1R Glucagon-like peptide 1 receptor P43220 133 
GNA11 
Guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1 P29992 116 
GNAQ Guanine nucleotide binding protein (G protein), Q Polypeptide P50148 116 
GNB2L1 
Guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1 P63244 112 
GPC3 Glypican 3 P51654 134 
H3F3B H3 histone, family 3B P84243 112 
HHEX Hematopietically Expressed Homeobox Q03014 134 
HIST1H1A Histone cluster 1, H1a Q02539  112 
HIST1H1C Histone cluster 1, H1c P16403 112 
HIST1H1D Histone cluster 1, H1d P16402 112 
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Gene Protein 
UniProt 
ID 
Ref. 
HIST1H1E Histone cluster 1, H1e P10412 112 
HIST1H2BA Histone cluster 1, H2ba Q96A08 112 
HIST1H2BB Histone Cluster 1, H2bb P33778 112 
HIST1H2BD Histone cluster 1, H2bd P58876 112 
HIST1H2BE Histone cluster 1, H2be P62807 112 
HIST1H2BH Histone cluster 1, H2bh Q93079 112 
HIST1H2BJ Histone cluster 1, H2bj P06899 112 
HIST1H2BK Histone cluster 1, H2bK O60814 112 
HIST1H2BL Histone cluster 1, H2bl Q99880 112 
HIST1H2BM Histone cluster 1, H2bm Q99879 112 
HIST1H2BN Histone cluster 1, H2bn Q99877 112 
HIST1H2BO Histone cluster 1, H2bo P23527 112 
HIST1H3E Histone cluster 1, H3e P68431 112 
HIST2H2BF Histone cluster 2, H2bF Q5QNW6 112 
HIST2H3C Histone cluster 2, H3c Q71DI3 112 
HIST3H3 Histone cluster 3, H3 Q16695 112 
HLA-B  HLA class I histocompatibility antigen, B-42 alpha chain P30480 135 
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 P09651 112 
HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 P22626 112 
HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 P51991 112 
HNRNPD Heterogeneous nuclear ribonucleoprotein Q14103 112; 136 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H1 (H) P31943 112 
HNRNPK Heterogeneous nuclear ribonucleoprotein K P61978 112 
HNRNPM Heterogeneous nuclear ribonucleoprotein M P52272 112 
HNRNPU Heterogeneous nuclear ribonucleoprotein U  Q00839 112 
HRAS Harvey Rat Sarcome Viral Oncogene Homolog P01112 137 
IBTK Inhibitor of Bruton agammaglobulinemia tyrosine kinase  Q9P2D0 112 
ICAM1 Intercellular adhesion molecule 1 P05362 138 
IFITM1 Interferon induced transmembrane protein 1 P13164 139 
IGSF8 Immunoglobulin superfamily, member 8 Q969P0 140 
IMMT Inner membrane protein, mitochondria Q16891 112 
INO80B INO80 complex subunit B Q9C086 131 
INPP4A Inositol polyphosphate-4-phosphatase, type I Q96PE3 112 
ITGA4 Integrin, alpha 4  P13612 141 
ITGB1 Integrin, beta 1 P05556 141,142 
JAK3 Janus kinase 3 P52333 110 
KHDRBS1 
KH domain containing, RNA binding, signal transduction 
associated 1 Q07666 112 
KHSRP KH-type splicing regulatory protein Q92945 112 
KIT 
v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog P10721 143 
LASP1 LIM and SH3 protein 1 Q14847 112 
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Gene Protein 
UniProt 
ID 
Ref. 
LDLR Low Density Lipoprotein Receptor P01130 144 
LRRC47 Leucine rich repeat containing 47 Q8N1G4 112 
LUC7L2 LUC7-like 2 (S.cerevisiae) Q9Y383 112 
MCM5 Minichrosome maintenance complex component 5 P33992 112 
MME Membrane Metallo-Endopeptidase (CD10) P08473 145 
MSN Moesin P26038 112 
MTHFD1 Methylenetetrahydrofolate dehydrogenase  P11586 112 
MYOC 
Myocilin, trabecular meshwork insucible glucocorticoid 
response Q99972 146 
NAMPT Nicotinamide phosphoribosyltransferase P43490 112 
NCL Nucleolin P19338 112 
NONO Non-POU domain containing, octame-binding Q15233 112 
NPM1 Nucleophosmin (nucleolar phosphoprotein B23, Numatrin) P06748 112 
NUDT21 Nudix (nucleoside diphosphate linked moiety X)-type motif 21 O43809 112 
PABPC1 poly(A) binding protein, cytoplasmic 1 P11940 112 
PCBP1 Poly(rC) binding protein 1 Q15365 112 
PCBP2 Poly(rC) binding protein 2 Q15366 112 
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 Q8NBP7 144 
PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor) Q653EL6 112 
PDIA6 Protein dissulfide isomerase family A, member 6 Q15084 112 
PFKP Phosphofrutokinase, platelet Q01813 112 
PI4K2A Phosphatidylinositosol 4-Kinase Type 2 alpha Q9BTU6 147 
PKM Pyruvate kinase, muscle P14618 112 
PKN1 Protein kinase N1 Q16512 112 
PSEN1 Presenilin 1 P49768 93 
PSEN2 Presenilin 2 P49810 93 
PTGFRN  Prostaglandin F2 receptor inhibitor P68104 115,148 
RAC1  Ras-related C3 botulinum toxin substrate 1 P63000 111 
RAC2 Ras-related C3 botulinum toxin substrate 1 P15153 112 
RBBP4 Retinoblastoma binding protein 4 Q09028 112 
RBBP6 Retinoblastoma binding protein 6 Q7Z6E9 149 
RGPD6 RANBP2-like and GRID domain containing 5/6 Q99666 112 
RPL11 Ribosomal proteil L11 P62913 112 
RPL12 Ribosomal protein L12 P30050 112 
RPL13 Ribosomal protein L13 P26373 112 
RPL17 Ribosomal protein L17 P18621 112 
RPL22 Ribosomal protein L22 P35268 112 
RPL23A Ribosomal protein L23a P62750 112 
RPL24 Ribosomal protein L24 P83731 112 
RPL27 Ribosomal protein L27 P61353 112 
RPL27A Ribosomal protein L27a P46776 112 
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Gene Protein 
UniProt 
ID 
Ref. 
RPL31 Ribosomal protein L31 P62899 112 
RPL35 Ribosomal protein L35 P42766 112 
RPL4 Ribosomal protein L4 P36578 112 
RPL5 Ribosomal protein L5 P46777 112 
RPL6 Ribosomal protein L6 Q02878 112 
RPLP0 Ribosomal protein, large, P0 P05388 112 
RPLP2 60S acidic ribosomal protein P2 P05387 112 
RPS13 Ribosomal protein S13 P26373 112 
RPS14 Ribosomal protein S14 P62263 112 
RPS15 Ribosomal protein S15 P62841 112 
RPS16 Ribosomal protein S16 P62249 112 
RPS18 Ribosomal protein S18 P62269 112 
RPS19 Ribosomal protein S19 P39019 112 
RPS2 Ribosomal protein S2 P15880 112 
RPS23 Ribosomal protein S23 P62266 112 
RPS25 Ribosomal protein S8 P62851 112 
RPS28 Ribosomal protein S28 P62857 112 
RPS3 ribosomal protein S3 P23396 112 
RPS3A Ribosomal protein S3A P61247 112 
RPS4X Ribosomal protei S4, X-linked P62701 112 
RPS4Y1 Ribosomal protein S4, Y-linked 1 P22090 112 
RPS6 Ribosomal protei S6 P62753 112 
RPS8 Ribosomal protein S26 P62241 112 
RPS9 Ribosomal protein S9 P46781 112 
RTF1 
Rtf1, Paf1/RNA polymerase II complex component, homolog (S. 
cerevisiae) Q92541 112 
SAMHD1 SAM domain and HD domain  Q9Y3Z3 112 
SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein Q8NC51 112 
SERPINB9 Serpin peptidase inhibitor, clade B, member 9 P50453 112 
SET  SET nulear proto-oncogene Q01105 112 
SF3B3 splicing factor 3b, subunit 3 Q15393 112 
SFPQ Splicing factor proline/glutamine-rich P23246 112 
SHC1 SHC-Transforming protein 1 P29353 150 
SNRPB small nuclear ribonucleoprotein polypeptide B and B1 P14678 112 
SNRPC small nuclear ribonucleoprotein polypeptide C P09234 112 
SNRPD1 Small nuclear ribonucleoprotein D1 polypeptide 16kDa P62314 112 
SNRPD3 Small nuclear ribonucleoprotein D3 polypeptide P62318 112 
SRSF3 serine/arginine-rich splicing factor 3 P84103 112 
SRSF8 serine/arginine-rich splicing factor 8 Q9BRL6 112 
STK10 Serine/threonine kinase 10 O94804 112 
STXBP5L  Syntaxin Binding Protein 5-like Q9Y2K9 151 
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Gene Protein 
UniProt 
ID 
Ref. 
SUPT16H Suppressor of Ty 16 homolog (S. Cerevisae) Q9Y5B9 112 
SYNCRIP Synaptotagmin binding, cytoplasmic RNA interacting protein O60506 112 
TFR2 Transferrin Receptor 2 Q9UP52 152 
TMPO Lamina-associated polypeptide 2, isoform alpha P42166 112 
TRAF6 TNF Receptor-associated Factor 6  Q9Y4K3 135 
TSPAN4 Tetraspanin 4 O14817 153 
TUBA1A Tubulin, alpha 1a Q71U36 112 
TUBA1B Tubulin, alpha 1b P68363 112 
TUBA1C Tubulin, alpha 1c Q9BQE3 112 
TUBA3C Tubulin, alpha 3c Q13768 112 
TUBA3D Tubulin, alpha 3d Q13768 112 
TUBA3E Tubulin, alpha 3e Q6PEY2 112 
TUBA4A Tubulin, alpha 4a P68366 112 
TUBA8 Tubulin, alpha 8 Q9NY65 112 
TUBB Tubulin, beta class I P07437 112 
TUBB2A Tubulin, beta 2A class IIa Q13885 112 
TUBB2B Tubulin, beta 2A class Iib Q9BVA1 112 
TUBB3 Tubulin, beta 3 class III  Q13509 112 
TUBB4A Tubulin, beta 4B class IVa P04350 112 
TUBB4B Tubulin, beta 4B class Ivb P68371 112 
TUBB6 Tubulin, beta 6 class V Q9BUF5 112 
TUBB7P Tubulin, beta 7, pseudogene I0CMK4 112 
TUBE1 Tubulin, epsilon 1 Q9UJTO 112 
TUFM Tu translation elongation factor, mitochondrial P49411 112 
UBXN1 UBX domain protein 1 Q04323 112 
VKORC1 vitamin K epoxide reductase complex, subunit 1 Q9BQB6 154 
WARS Tryptophanyl-Trna synthetase P23381 112 
ZBTB16 Zinc finger and BTB domain containing 16 Q05516 131 
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Table 2. Full list of proteins with the associated score extracted from the network using GeneMania.  
Gene 
Symbol 
Score 
Gene 
Symbol 
Score 
Gene 
Symbol 
Score 
STK10 100.00 CD14 97.34 RTF1 94.89 
TUBE1 100.00 RBBP6 97.28 ALYREF 94.75 
STXBP5L 99.87 PSEN2 97.22 CCT4 94.73 
TUBA3D 99.87 EIF3I 97.22 RPS3A 94.71 
RPS4Y1 99.86 ADAM10 97.17 NONO 94.70 
RGPD6 99.82 HNRNPA3 97.03 TUFM 94.69 
HIST1H2BE 99.76 RPS23 96.99 HLA-B 94.63 
H3F3B 99.63 TUBB3 96.99 GNAQ 94.60 
INPP4A 99.61 RPLP2 96.98 MCM5 94.42 
GGT1 99.60 BCR 96.90 TUBB4B 94.40 
CD81 99.60 PDCD4 96.86 RPS3 94.38 
PTGFRN 99.57 RPL5 96.86 SNRPD1 94.22 
HIST1H2BH 99.53 ITGA4 96.82 KHSRP 94.19 
HIST2H2BF 99.50 GNA11 96.77 DDX3X 94.16 
HIST1H2BM 99.50 JAK3 96.75 CFL1 94.13 
IGSF8 99.50 PFKP 96.70 PABPC1 94.11 
CD53 99.49 SNRPC 96.69 PKM 94.11 
TUBA8 99.46 TUBB2A 96.66 EEF1D 94.05 
CRIP1 99.43 RPL27A 96.64 CCT3 94.03 
PI4K2A 99.30 RPS25 96.63 SF3B3 93.97 
HIST1H2BN 99.30 KIT 96.62 EIF4A1 93.96 
IFITM1 99.27 EIF3E 96.57 EWSR1 93.80 
TSPAN4 99.23 EIF3H 96.57 ACTN1 93.78 
EIF3CL 99.15 RPL27 96.56 SNRPB 93.74 
PCSK9 99.13 ZBTB16 96.55 PCBP1 93.71 
HIST1H3E 99.13 RPL35 96.55 HRAS 93.60 
IBTK 99.08 RPL17 96.54 TUBB 93.51 
HIST1H1D 99.06 RPS14 96.52 PSEN1 93.40 
HHEX 99.00 TUBA1B 96.46 DDX17 93.32 
SERPINB9 98.96 EIF4A2 96.43 KHDRBS1 93.07 
GPC3 98.96 MTHFD1 96.36 SYNCRIP 93.04 
DDX3Y 98.94 RPL4 96.34 SET 93.01 
FAM98B 98.88 EIF3B 96.26 DHX15 92.89 
TFR2 98.86 RPL22 96.26 HNRNPM 92.88 
DLG5 98.85 IMMT 96.23 RBBP4 92.84 
HIST1H2BD 98.85 PKN1 96.22 SNRPD3 92.73 
HIST1H2BA 98.67 RPL12 96.21 HNRNPA2B1 92.71 
INO80B 98.60 RPL13 96.21 EZR 92.63 
CD19 98.59 RPS13 96.19 GAPDH 92.44 
CD46 98.59 LUC7L2 96.19 AKT1 92.38 
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Gene 
Symbol 
Score 
Gene 
Symbol 
Score 
Gene 
Symbol 
Score 
CTSC 98.55 HIST1H1C 96.14 GNB2L1 92.37 
CD82 98.49 RAC2 96.10 EEF1A1 92.35 
TUBA3C 98.46 CD4 96.09 HNRNPD 92.33 
HIST1H2BO 98.43 RPS9 96.06 NCL 92.28 
ANP32B 98.40 WARS 96.03 DDX5 91.57 
HIST1H2BK 98.37 RPS16 96.02 RAC1 91.54 
CD63 98.33 GLP1R 95.98 ADRB2 91.51 
TUBA3E 98.29 UBXN1 95.93 FLNA 91.43 
ATP5O 98.18 TMPO 95.83 ACTB 91.41 
EIF3G 98.16 NUDT21 95.82 ITGB1 91.35 
HIST1H2BJ 98.14 RPS18 95.74 CSNK2B 91.27 
LASP1 98.12 FUBP1 95.74 HNRNPK 91.12 
ICAM1 98.08 MME 95.71 HNRNPH1 90.93 
NAMPT 98.07 RPL6 95.70 HNRNPU 90.86 
RPS28 98.04 CPSF6 95.69 SHC1 89.79 
TUBB2B 98.02 TUBA4A 95.68 TRAF6 89.08 
CNN2 98.01 ATP5A1 95.64 NPM1 88.34 
HIST1H1A 97.95 RPL24 95.63 HNRNPA1 88.10 
EIF3K 97.92 RPL11 95.63 APP 82.15 
HIST1H2BB 97.92 SERBP1 95.62 UBC 8.72 
LRRC47 97.87 EEF1A2 95.59 MAGOH 6.20 
CD74 97.86 ACTN4 95.57 EIF4A3 5.73 
CR2 97.80 RPL23A 95.54 CDK2 4.56 
SAMHD1 97.80 EIF3C 95.53 PAN2 4.09 
TUBB6 97.76 VKORC1 95.52 TARDBP 3.33 
PDIA6 97.63 RPS4X 95.49 UBL4A 3.11 
RPL31 97.57 RPS6 95.41 EIF3M 3.07 
CLDN1 97.57 PCBP2 95.41 SF3A2 3.04 
HIST2H3C 97.57 MSN 95.38 SRRM2 3.01 
RPS15 97.54 RPS19 95.36 EIF3D 2.99 
FAU 97.53 HIST3H3 95.35 RPA2 2.54 
CFL2 97.53 TUBA1A 95.34 RPA1 2.50 
TUBA1C 97.50 EIF3F 95.33 RPA3 2.44 
LDLR 97.49 RPS8 95.31 YWHAZ 2.41 
CD9 97.49 RPS2 95.22 CSNK2A2 2.33 
EIF3L 97.41 EIF3A 95.17 SRRM1 2.27 
HIST1H2BL 97.40 SUPT16H 95.16 IPO11 1.69 
HIST1H1E 97.36 SFPQ 95.04 EIF3J 1.58 
TUBB4A 97.36 SRSF3 95.01 HADHA 1.50 
MYOC 97.34 RPLP0 94.98   
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Appendix 2 
Culture media and Solutions 
I. Bacterial Media  
 
  LB ( Luria-Bertani) Medium 
To 950 ml of deonizated H20 add: 
LB  25 g 
Agar   15 g (for plates only) 
Antibiotic   
Shake until the solutes have dissolved. Adjust the volume of the solution to 1 l with 
deonizated H20. Sterilize by autoclaving. Add antibiotic to a final concentration of: 30 
µg/ml kanamycin or 50 µg/ml ampicillin. 
 
II. Cell culture Solutions  
 
 PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
 8 mM Sodium Phosphate 
 2 mM Potassium Phosphate 
 140 mM Sodium Chloride 
 10 mM Potassium Chloride 
Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
 10% FBS MEM:F12 (1:1) 
 4.805 g MEM 
 5.315 g F12 
 1.5 g NaHCO3 
 0.055 g Sodium Pyruvate 
 10 ml Streptomycin/Penicillin/Amphotericin solution 
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 100 ml 10% FBS 
 2.5 ml L-glutamine (200 mM stock solution) 
Dissolve in deionised H2O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 ml with 
deionised H2O. 
 
 10% FBS F12 Nutrient Mixture + L-Glutamine  
-10.6 g F12  
-1.5 g NaHCO3 
-0,146 g (1mM) L-Glutamine 
- 10 ml Streptomycin/Penicillin/Amphotericin solution (AAs) 
- 100 ml 10% FBS 
Dissolve in deionised H2O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 ml 
with deionised H2O. 
 
 10% FBS DMEM 
-13.4 g DMEM 
-3.7 g NaHCO3 
- 10 ml Streptomycin/Penicillin/Amphotericin solution (AAs) 
- 100 ml 10% FBS 
Dissolve in deionised H2O. Adjust the pH to 7.2-7.3. Adjust the volume to 1000 
ml with deionised H2O. 
 
 Earl’s balance solution (Sebss) 
- 1.8 mM CaCl2 
- 5.4 mM KCl 1.8 mM CaCl2 
-5.4 mM KCl, 0.81 mM MgSO4,  
-25.0 mM NaHCO3, 
- 1.0 mM NaH2PO4, 116.4 mM NaCl,  
-5.5 mM D-glucose, 2.5 mM Na–pyruvate,  
-41.8 mM Na–lactate and  
-0.3% BSA 
 
III. Western Blot Solutions 
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 LGB (lower gel buffer) (4x) 
To 900 ml of deionised H2O add: 
 181.65 g of Tris 
 4 g of SDS 
Mix until the solutes have dissolved. Adjust pH to 8.9 and adjust the volume to 1 L with 
deionised H2O. 
 
 UGB (Upper gel buffer) (4x) 
To 900 ml of deionised H2O add: 
 75.69 g of Tris 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L 
with deionised H2O. 
 
 10% APS (ammonium persulfate) 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
 
 10% SDS (sodium dodecilsulfate) 
In 10 ml of deionised H2O dissolve 1 g of SDS. 
 
 Loading Gel Buffer (4x) 
 2.5 ml 1M Tris solution (pH 6.8) 2.5 ml (250 mM) 
 0.8 g SDS (8%) 
 4 ml Glicerol (40%) 
 2 ml β-mercaptoethanol (2%) 
 1 mg Bromofenol blue (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at room 
temperature. 
 
 1 M Tris (pH 6.8) solution 
To 150 ml of deionised H2O add: 
 30.3 g Tris base 
Adjust the pH to 6.8 and adjust the final volume to 250 ml with deionised H2O. 
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 10x Running Buffer 
 30.3 g Tris (250 mM) 
 144.2 g Glycine (2.5 M) 
 10 g SDS (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1l. 
 
 Stacking and resolving gel 
Type of Gel Stacking Resolving 
Polyacrylamide percentage 3.5 % 5 % 20 % 
H2O 13.2 ml 17.4 ml 2.2 ml 
Acrylamide stock mixture 2.4 ml 5 ml 20 ml 
UGB (5x) 4 ml n/a n/a 
LGB (4x) n/a 7.5 ml 7.5 ml 
10% SDS 200 μL n/a n/a 
10% APS 200 μL 150 μL 150 μL 
TEMED 20 μL 15 μL 15 μL 
 
 Transfer Buffer (1x) 
 3.03 g Tris (25 mM) 
 14.41 g Glycine (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 
800 ml with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
 
 10x TBS (Tris buffered saline) 
 12.11 g Tris (10 mM) 
 87.66 g NaCl (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 l with deionised H2O. 
 
 10x TBST (TBS+Tween) 
 12.11 g Tris (10 mM) 
 87.66 g NaCl (150 mM) 
 10 ml Tween-20 (0.01%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
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IV. Immunofluorescence Solutions 
 
 4% Paraformaldehyde 
For a final volume of 100 ml, add 4 g of paraformaldehyde to 25 ml deionised H2O. 
Dissolve by heating the mixture at 58°C while stirring. Add 1-2 drops of 1 M NaOH to 
clarify the solution and filter through a 0.2 μM filter. Add 50 ml of PBS 2x and adjust the 
volume to 100 ml with deionised H2O. 
 
 
 
 
